var title_f25_59_26544="Red cells in the spleen";
var content_f25_59_26544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Red blood cell deformation in splenic cords",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning electron microphotograph of normal murine red blood cell passing from a splenic cord (below) through the sinusoidal barrier and into the splenic sinusoid (above). Note the deformation necessary to squeeze through the slit in the sinusoidal wall and how a surface area depleted spherocyte would be incapable of transversing the barrier.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mohandas Narla, ScD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26544=[""].join("\n");
var outline_f25_59_26544=null;
var title_f25_59_26545="Laparoscopic primary repair of hiatal defect";
var content_f25_59_26545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic primary repair of hiatal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intraoperative photograph shows the primary repair of the hiatal defect. The crura of the diaphragm are sutured posterior to the esophagus, as indicated by the arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26545=[""].join("\n");
var outline_f25_59_26545=null;
var title_f25_59_26546="Menopause";
var content_f25_59_26546=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Menopause (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/59/26546/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26546/contributors\" id=\"au2180\">",
"       Robert F Casper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/59/26546/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26546/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26546/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/59/26546/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26546/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/59/26546?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Menopause is defined as the time in a woman's life, usually between 45 and 55 years, when the ovaries stop producing eggs and menstrual periods end. The",
"     <strong>",
"      average",
"     </strong>",
"     age of menopause is 51 years.",
"    </p>",
"    <p>",
"     Years before you stop having menstrual periods, changes in your hormone levels can lead to some of the symptoms of menopause. In addition to irregular periods, the most common symptoms are hot flashes, night sweats, sleep problems, and vaginal dryness.",
"    </p>",
"    <p>",
"     Menopause is a normal part of a woman's life and does not always need to be treated. However, the changes that happen before and after menopause can be disruptive. If you have bothersome symptoms, effective treatments are available.",
"    </p>",
"    <p>",
"     More detailed information about menopause is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"      \"Clinical manifestations and diagnosis of menopause\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AM I GOING THROUGH MENOPAUSE?",
"     </span>",
"    </p>",
"    <p>",
"     A number of terms are used to describe the time before and after you stop having menstrual periods.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The menopausal transition starts when your menstrual periods first begin to change (become more or less frequent, more or less bleeding, skipped periods), and ends when you have your final menstrual period. Many people refer to this transition as \"perimenopause.&rdquo;",
"      </li>",
"      <li>",
"       Menopause occurs when it has been 12 months since your last menstrual period.",
"      </li>",
"      <li>",
"       Postmenopause is the time after menopause.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The average age of menopause is 51 years, although the age range can vary between 45 and 55 years. Women who become menopausal before age 40 are considered to have an abnormally early menopause (called premature ovarian failure or primary ovarian insufficiency). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"      \"Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you are 45 years or older and you have not had a menstrual period in 12 months, there is a good chance that you are menopausal. Most women in this group do not need any lab testing to confirm menopause, especially if they are having menopausal symptoms such as hot flashes or vaginal dryness.",
"    </p>",
"    <p>",
"     If you are less than 45 years old and you stop having periods or if you have questions about menopausal symptoms, talk to your doctor or nurse. You may need further testing to see if menopause, or another problem, is the cause of your symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      After hysterectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you do not have a uterus (eg, after hysterectomy) but you still have ovaries, it can be hard to know when you are menopausal because you will not have menstrual periods. You may develop menopausal symptoms as your ovaries stop working and your blood levels of estrogen begin to fall. If you are having bothersome symptoms of menopause after hysterectomy, talk to your doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      MENOPAUSE AND MENSTRUAL PERIODS",
"     </span>",
"    </p>",
"    <p>",
"     Many women begin to notice changes in their menstrual periods during the menopausal transition (perimenopause). These changes may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Having menstrual periods more or less often than usual (eg, every five to six weeks instead of every four)",
"      </li>",
"      <li>",
"       Having bleeding that lasts for fewer days than before",
"      </li>",
"      <li>",
"       Skipping one or more menstrual periods",
"      </li>",
"      <li>",
"       Having symptoms of menopause (see",
"       <a class=\"local\" href=\"#H7\">",
"        'Menopause symptoms'",
"       </a>",
"       below)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Abnormal bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;It can be hard to know if vaginal bleeding is abnormal when you are near menopause. In general, you should see your doctor or nurse if you have the following symptoms:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Vaginal bleeding more often than every three weeks",
"      </li>",
"      <li>",
"       Excessive, heavy menstrual bleeding",
"      </li>",
"      <li>",
"       Spotting between your periods",
"      </li>",
"      <li>",
"       Vaginal bleeding after menopause (even if it's just a spot of blood)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Irregular vaginal bleeding may be a normal part of menopause or it may be a sign of a problem. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Menopause and birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although most women are less likely to become pregnant (without infertility treatment) after age 45, it is still possible, especially if you are having monthly periods and having sex regularly. If you do not want to become pregnant, you should continue to use some form of birth control until you are menopausal. Once you become menopausal, you cannot get pregnant.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you are using a hormonal method of birth control, like pills, an injection, a vaginal ring, or a skin patch, talk to your doctor or nurse to find out when you should stop. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Alternatively, you can switch to a non-hormonal method of birth control (condoms, spermicide) sooner. If you are over 45, using a non-hormonal method of birth control, and you have not had a menstrual period for 12 months, you can stop using birth control altogether.",
"      </li>",
"      <li>",
"       If you are using an IUD, you can have it removed when it expires (after 10 years for most copper IUDs, after five years for levonorgestrel IUDs [eg, Mirena]). You can also ask to have the IUD removed sooner.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      MENOPAUSE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     As the ovaries stop working, levels of estrogen fall, leading to the typical symptoms of menopause. Some women have few or no menopausal symptoms while other women have bothersome symptoms that interfere with their life. These symptoms often begin during the menopause transition, before you stop having periods.",
"    </p>",
"    <p>",
"     The most common symptoms of menopause include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hot flashes &mdash; Hot flashes typically begin as a sudden feeling of heat in the upper chest and face. The hot feeling then spreads throughout the body and lasts for two to four minutes. Some women sweat during the hot flash and then feel chills and shiver when the hot flash ends. Some women have a feeling of anxiety or heart palpitations during the hot flash. Hot flashes can occur once or twice each day or as often as once per hour during the day and night.",
"       <br/>",
"       <br/>",
"       Hot flashes usually begin well before your last menstrual period. It is not clear what causes hot flashes. Most women who have hot flashes will continue to have them for about four years (on average). (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"        \"Menopausal hot flashes\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Night sweats &mdash; When hot flashes happen during sleep, they are called night sweats. Night sweats may cause you to sweat through your clothes and wake you from sleep because you are hot or cold. This can happen one or more times per night. Waking frequently can make it hard to get a good night's sleep. As a result of interrupted sleep, many women develop other problems, such as fatigue, irritability, trouble concentrating, and mood swings.",
"      </li>",
"      <li>",
"       Sleep problems &mdash; During the transition to menopause, some women begin to have trouble falling asleep or staying asleep, even if night sweats are not a problem. Sleep problems can cause you to feel tired and irritable the next day. Effective treatments for sleep problems are available. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"        \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Vaginal dryness &mdash; As the levels of estrogen in the blood fall before and during menopause, the tissues inside the vagina and urethra (the tube from the bladder to the outside of the body) can become thin and dry. This can cause you to have vaginal dryness or irritation or to have pain or dryness with sex. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"        \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Depression &mdash; During the menopausal transition, some women develop new problems with mood, such as sadness, difficulty concentrating, feeling uninterested in normal activities, and sleeping too much or having trouble staying asleep. Women with a past history of depression can feel more blue moods during the menopause transition. If you have any symptoms of depression or blues that will not go away, talk to your doctor or nurse. There are a number of effective treatments available. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"        \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      MENOPAUSE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Not all women will need treatment for menopausal symptoms, especially if the symptoms are mild. In fact, there are things you can do on your own that might help you cope with the symptoms you have (",
"     <a class=\"graphic graphic_table graphicRef82045 \" href=\"UTD.htm?28/23/29051\">",
"      table 1",
"     </a>",
"     ). For women whose symptoms are really bothersome, there are several treatment options:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Postmenopausal hormone therapy &mdash; Women with bothersome hot flashes can usually get relief with postmenopausal hormone therapy. For women with a uterus, this would be a combination of estrogen and a progesterone-like medication. Women who do not have a uterus (eg, after a hysterectomy) need only estrogen. Hormone therapy is available in a pill that you take by mouth; a skin patch; a vaginal ring; and a skin gel, cream, or spray. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"        \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Hormone therapy alternatives &mdash; If you are bothered by hot flashes but you cannot take or would prefer to avoid hormone therapy, there are alternatives. Although hormone therapy is the most effective treatment for hot flashes, non-hormonal alternatives are a good option for many women. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"        \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Vaginal treatments &mdash; There are several treatment options for women with vaginal dryness, including vaginal estrogen. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"        \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785010551\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5515189\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=see_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5515197\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"      Menopausal hot flashes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/menopause.html\">",
"      www.nlm.nih.gov/medlineplus/menopause.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/menopause.cfm\">",
"      www.hormone.org/public/menopause.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       North American Menopause Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.menopause.org/\">",
"      www.menopause.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/59/26546/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/59/26546?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26546/abstract/1\">",
"      National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26546/abstract/2\">",
"      Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; :CD002978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26546/abstract/3\">",
"      Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15:584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_59_26546=[""].join("\n");
var outline_f25_59_26546=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AM I GOING THROUGH MENOPAUSE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           MENOPAUSE AND MENSTRUAL PERIODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           MENOPAUSE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           MENOPAUSE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/23/29051\" title=\"table 1\">",
"           Coping with menopause PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26547="Perineal vessels";
var content_f25_59_26547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Arteries of the female perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26547=[""].join("\n");
var outline_f25_59_26547=null;
var title_f25_59_26548="Wrist hypermobility";
var content_f25_59_26548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61525%7ERHEUM%2F62841%7ERHEUM%2F67020%7ERHEUM%2F81152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61525%7ERHEUM%2F62841%7ERHEUM%2F67020%7ERHEUM%2F81152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Joint laxity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laxity of the wrist allows approximation of the thumb to the patient's ipsilateral forearm. Joint laxity is a crucial feature of the hypermobility syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow hypermobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laxity of the elbow with greater than 10 degrees of joint extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed. Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee hypermobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 146px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laxity of the knee with greater than 10 degrees of joint extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal hypermobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 189px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While keeping the knees locked straight, the person with joint laxity can bend and lay palms to floor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Sheon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26548=[""].join("\n");
var outline_f25_59_26548=null;
var title_f25_59_26549="Indacaterol: Drug information";
var content_f25_59_26549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indacaterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/43/4790?source=see_link\">",
"    see \"Indacaterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13388360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13897426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arcapta&trade; Neohaler&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13898949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Onbrez&reg; Breezhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12963964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13388390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      COPD (maintenance):",
"     </b>",
"     Inhalation: One inhalation (75 mcg/inhalation) once daily; maximum: 1 inhalation once daily.",
"     <b>",
"      Note:",
"     </b>",
"     A dose of 75-300 mcg once daily is recommended by the 2013 Updated GOLD Guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13388391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13388668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13388669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13824114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arcapta&trade; Neohaler&trade;: 75 mcg/capsule (30s) [contains contains lactose~25 mg/capsule]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13388363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13388362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000MedG.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000MedG.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13388404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation:",
"     <b>",
"      For inhalation using Neohaler&trade; inhaler (U.S.) or Onbrez&reg; Breezhaler&reg; (Canada) only",
"     </b>",
"     . Do",
"     <b>",
"      not",
"     </b>",
"     swallow indacaterol capsules. Use the new inhaler included with each prescription. Do not remove capsules from blister until immediately before use. Use at the same time each day. Not to be used for the relief of acute attacks. Not for use with a spacer device. Do not wash mouthpiece; inhalation device should be kept dry. Discard any capsules that are exposed to air and not used immediately.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12963958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13388371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Respiratory: Cough (post inhalation 7% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (5%), oropharyngeal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Dizziness, hypersensitivity reaction, palpitation, paradoxical bronchospasm, pruritus, rash, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13388367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indacaterol or any component of the formulation; monotherapy in the treatment of asthma (ie, use without a concomitant long-term asthma control medication, such as an inhaled corticosteroid).",
"     <b>",
"      Note:",
"     </b>",
"     Indacaterol is not FDA approved for treatment of asthma.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13388368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs) increase the risk of asthma-related deaths. The safety and efficacy of indacaterol in the treatment of asthma have not been established.",
"     </b>",
"     In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. It is unknown if indacaterol increases asthma-related deaths.  No data exist associating LABA use with an increased risk of death in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Bronchospasm: Rarely, paradoxical, life-threatening bronchospasm may occur with use of inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists; distinguish from inadequate response, discontinue medication immediately, institute alternative therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Hypersensitivity: Hypersensitivity reactions may occur; discontinue therapy if patient develops an allergic reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, or HF); beta-agonists may cause elevation in blood pressure and heart rate. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also produce changes in the ECG (eg, T-wave flattening, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, ST segment depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	COPD: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute bronchospastic episodes of COPD; always prescribe indacaterol with an inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist and educate patient on appropriate use. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating COPD. Do not increase the indacaterol dose or frequency beyond what is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hyperthyroidism: Use with caution in patients with hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Seizure disorders: Use with caution in patients with seizure disorders; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; LABA: Do not use with other long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists; deaths and significant cardiovascular effects have been reported with excessive sympathomimetic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Lactose: Product contains lactose; allergic reactions possible in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13462006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein, UGT1A1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13462004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: May enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Indacaterol may enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13388364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13388365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Beta agonists may interfere with uterine contractility if administered during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13388366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Arcapta Neohaler Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (1): $6.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13388406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , FVC, and/or other pulmonary function tests; serum potassium, serum glucose; blood pressure, heart rate; CNS stimulation. Monitor for increased use of short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist inhalers; may be marker of a deteriorating condition. Monitor for changes in risk factors (eg, environmental exposure, smoking status).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hirobriz Breezhaler (EE);",
"     </li>",
"     <li>",
"      Onbrez Breezhaler (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, HK, HN, ID, IE, IL, IN, MY, NL, NO, NZ, PH, PL, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Onbrize Breezhaler (AR, BR, CN, CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13388377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate; acts locally in the lung.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13388379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic: Inhalation: 43% to 45% bioavailable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; hydroxylated via CYP3A4, CYP2D6, and CYP1A1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 40-56 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: ~15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (&gt;90%; 54% as unchanged drug [after oral administration]); urine (&lt;2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balint B, Watz H, Amos C, et al, &ldquo;Onset of Action of Indacaterol in Patients With COPD: Comparison With Salbutamol and Salmeterol-Fluticasone,&rdquo;",
"      <i>",
"       Int J Chronic Obstructive Pulm Dis",
"      </i>",
"      , 2010, 5:311-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/20856830/pubmed\" id=\"20856830\" target=\"_blank\">",
"        20856830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahl R, Chung KF, Buhl R, et al, &ldquo;Efficacy of a New Once Daily Long-Acting Inhaled Beta2-Agonist Indacaterol versus Twice-Daily Formoterol in COPD,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 2010, 65(6):473-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/20522841/pubmed\" id=\"20522841\" target=\"_blank\">",
"        20522841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman G, Siler T, Prasad N, et al, &ldquo;Efficacy and Safety of Indacaterol 150 mcg Once Daily in COPD:  A Double-Blind, Randomised, 12-Week Study,&rdquo;",
"      <i>",
"       BMC Pulm Med",
"      </i>",
"      , 2010, 10:11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/20211002/pubmed\" id=\"20211002\" target=\"_blank\">",
"        20211002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for the Diagnosis, Management and Prevention of COPD",
"      </i>",
"      , Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013. Available at file://www.goldcopd.com",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khindri S, Sabo R, Harris S, et al, &ldquo;Cardiac Safety of Indacaterol in Healthy Subjects: A Randomized, Multidose, Placebo- and Positive-Controlled, Parallel-Group Thorough QT Study,&rdquo;",
"      <i>",
"       BMC Pulm Med",
"      </i>",
"      , 2011, 11:31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/21615886/pubmed\" id=\"21615886\" target=\"_blank\">",
"        21615886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moen MD, &ldquo;Indacaterol in Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2010, 70(17):2269-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/59/26549/abstract-text/21080743/pubmed\" id=\"21080743\" target=\"_blank\">",
"        21080743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Medicines Agency , &ldquo;Onbrez Breezhaler (indacaterol): EPAR Summary for the Public, 2009.&rdquo; Available at  file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001114/WC500053733.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16792 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-5A4195AC92-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26549=[""].join("\n");
var outline_f25_59_26549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388360\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897426\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13898949\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12963964\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388390\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388391\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388668\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388669\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13824114\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388363\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388362\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388404\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12963958\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388371\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388367\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388368\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13462006\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13462004\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388364\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388365\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388366\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322908\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388406\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992823\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388377\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388379\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/43/4790?source=related_link\">",
"      Indacaterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26550="Exenatide: Patient drug information";
var content_f25_59_26550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Exenatide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     see \"Exenatide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F595798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bydureon&trade;;",
"     </li>",
"     <li>",
"      Byetta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14204425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Byetta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647170",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bydureon&trade; has been shown to cause thyroid cancer in some animals. Call your doctor right away if you have a neck mass, trouble breathing, trouble swallowing, or have hoarseness that will not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to exenatide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, very bad kidney disease, type 1 diabetes, or thyroid cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lump on your neck.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most often taken with at least 2 other drugs. Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix this drug in the same syringe with insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give this drug at some other site from where you gave your insulin if you are also getting insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Byetta&reg;:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take within 60 minutes before the morning and evening meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare pen before first use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shoot 1 test dose into the air.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dial the dose into the window before each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Attach new needle before each dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bydureon&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take the same day each week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Byetta&reg;:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bydureon&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is 3 or more days to the time of your next dose, take the missed dose as soon as you think about it and go back to your normal day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is 1 or 2 days to the time of your next dose, skip the missed dose and go back to your normal day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Byetta&reg;:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not store pen with the needle on it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened and opened pens in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3647182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bydureon&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3647190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store at room temperature for 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right away after mixing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11347 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26550=[""].join("\n");
var outline_f25_59_26550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595798\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14204425\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023913\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023915\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023914\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023919\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023920\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023922\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023917\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023918\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023923\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023924\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=related_link\">",
"      Exenatide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26551="Role of allergy in atopic dermatitis (eczema)";
var content_f25_59_26551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of allergy in atopic dermatitis (eczema)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Jonathan M Spergel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26551/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/59/26551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy with regard to the role of allergy in atopic dermatitis (eczema). Some clinicians believe that allergic responses to aeroallergens are a rare cause of exacerbations of atopic dermatitis (AD) and that food allergy is generally not a factor. Other clinicians believe that allergy plays a strong role in exacerbating AD in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/1\">",
"     1",
"    </a>",
"    ]. They believe that food allergies trigger symptoms primarily in young children and environmental allergens play a greater role in older children and adults.",
"   </p>",
"   <p>",
"    Despite its name, atopic dermatitis itself is not a type I allergy, nor is it necessarily associated with allergic sensitization. However, overall, the data indicate that allergy plays a role in selected patients with AD.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of AD, as well as the role of delayed type hypersensitivity to chemicals in topical medications and skin care products in exacerbating AD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATOPIC ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AD have higher rates of allergic diseases than the general population. Up to 80 percent of children with AD develop asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic rhinitis later in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/2\">",
"     2",
"    </a>",
"    ]. The converse is true as well; a higher rate of AD is seen in teenagers with asthma than those without asthma (RR 4.5, 95% CI 3.1-6.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/3\">",
"     3",
"    </a>",
"    ]. Ten to 20 percent of patients with AD have food-induced",
"    <span class=\"nowrap\">",
"     urticaria/anaphylaxis",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], compared with 1 to 3 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In infants with eczema, the prevalence of IgE-mediated food allergy confirmed by double-blind, placebo-controlled food challenge, except in patients with a history of anaphylaxis and positive specific IgE, ranges from 33 to 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/4,8-12\">",
"     4,8-12",
"    </a>",
"    ]. Earlier onset (&lt;3 months of age) and more severe AD is associated with high egg, milk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peanut-specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with AD and concomitant egg, peanut, or dust mite allergy are more likely to have AD that persists beyond five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AD is also associated with elevated serum IgE. A high total serum IgE level is a strong risk factor for AD in children from birth to six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/15\">",
"     15",
"    </a>",
"    ]. IL-13 variants are associated with slightly higher total IgE levels and sensitization to food allergens, most commonly hen's egg, in young children with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/16\">",
"     16",
"    </a>",
"    ]. In adults, elevated total IgE is associated with persistent eczema with a wide distribution after 10 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALLERGEN SENSITIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have demonstrated an increased rate of sensitization to both food and aeroallergens in patients with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/18\">",
"     18",
"    </a>",
"    ]. On average, 50 percent of children and 35 percent of adults with AD are sensitized to common allergens. However, these proportions vary widely (7 to 78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of allergen sensitization is not proof of clinically relevant allergy. Confirming clinical reactivity is especially important when food allergies are suspected in young children, since avoidance of food allergens can put growing children at nutritional risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=see_link\">",
"     \"Nutritional issues in food allergy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Food allergies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infants and young children with AD are more commonly sensitized to foods (wheat and egg sensitization are most prevalent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Children over five years and adults are more commonly sensitized to aeroallergens (dust mite sensitization is most prevalent in both children and adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/22\">",
"     22",
"    </a>",
"    ]. A higher rate of dust mite sensitization in patients with AD is also seen with atopy patch testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have compared allergic sensitization patterns in patients with AD from different countries. The findings demonstrate a wide variability in sensitization patterns between countries and confirm that allergic sensitization is associated with higher socioeconomic status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the International Study of Asthma and Allergies in Childhood (ISAAC), 28,591 children aged 8 to 12 years from 20 countries were examined for flexural eczema and skin tested to at least six common aeroallergens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/24\">",
"       24",
"      </a>",
"      ]. The point prevalence of AD ranged from &lt;1 to 14 percent. The percentage of children who had at least one positive skin prick test ranged from 0 to 74 percent. The association of AD and allergic sensitization was stronger in affluent versus nonaffluent countries (OR 2.69, 95% CI 2.31-3.12 versus 1.17, 0.81-1.70).",
"     </li>",
"     <li>",
"      Similar findings were seen in a study of five- to six-year-old children with AD and allergic sensitization in East and West Germany [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/25\">",
"       25",
"      </a>",
"      ]. Only 36 percent of children with AD in East Germany were skin prick test positive to at least one food or inhalant allergen, compared with 50 percent of children with AD in West Germany.",
"     </li>",
"     <li>",
"      In a randomized early prevention trial for asthma, baseline evaluation of 2184 infants with AD from atopic families included total serum IgE and specific IgE to eight food and inhalant allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/26\">",
"       26",
"      </a>",
"      ]. A total of 53 percent of infants had IgE &ge;30",
"      <span class=\"nowrap\">",
"       kU/L,",
"      </span>",
"      with the percentage ranging from 35 to 67 percent in 12 different countries. Ninety-six percent of the infants had complete specific IgE results. Over half of these infants were sensitized (specific IgE &ge; 0.70",
"      <span class=\"nowrap\">",
"       kU/L);",
"      </span>",
"      19 percent, monosensitized; and 37 percent, polysensitized. Nearly one-half were sensitized to at least one food and one-third were sensitized to one or more inhalant allergens (percentages &mdash; egg white, 42; cow's milk, 27; peanut, 24; house dust mite, 21; cat dander, 13; tree pollen, 8; grass pollen, 8; and Alternaria, 4). Rates of specific allergen sensitization varied widely between countries. As an example, the rate of egg white sensitization was 54 percent in Australia and 23 percent in Belgium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FOOD ALLERGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of dermatologic manifestations are believed to be associated with food allergies:",
"    <span class=\"nowrap\">",
"     urticaria/anaphylaxis",
"    </span>",
"    and food-exacerbated AD. Only the second type of reaction is examined here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In food-exacerbated AD reactions, ingestion of the food acutely is thought to cause a flare of the patient's atopic dermatitis (increased erythema and pruritus of eczematous lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/27\">",
"     27",
"    </a>",
"    ]. The flare occurs within minutes to a few hours if the reaction is IgE-mediated, but may take hours to days if the reaction is non-IgE mediated. The patient has persistent lesions if the food is eaten chronically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of food allergy involves two steps: identification of the food sensitization and confirmation of clinical allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/28\">",
"     28",
"    </a>",
"    ]. Identification involves history taking and allergy testing. Patients are unlikely to have food allergies as a trigger of their severe AD if they have periods of clear skin on a regular diet without medication. Food allergy is a more likely trigger if the onset or worsening of AD correlates with exposure to the food. Infants with AD and food allergy may have additional findings that suggest the presence of food allergy, such as vomiting, diarrhea, and failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food allergy can be evaluated by either prick skin testing or in vitro testing for food-specific IgE. Eosinophilia may be a predictor of food allergy in patients with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with AD, the rate of sensitization to foods ranges from 30 to 80 percent, depending upon the population, but the actual rate of confirmed food allergy is much lower [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/20,31-33\">",
"     20,31-33",
"    </a>",
"    ]. As an example, 52 percent of children in a birth cohort who developed AD during the first six years of life were sensitized to at least one food allergen, but only 15 percent had challenge-confirmed food allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/20\">",
"     20",
"    </a>",
"    ]. Wheat was the most common food to which patients were sensitized, but egg was the most common food to which patients were allergic, as confirmed by food challenge.",
"   </p>",
"   <p>",
"    Most patients with food sensitization and AD fall into a gray area in which the test is neither negative nor above the 95 percent positive predictive value (PPV). Other patients may have suspected non-IgE mediated food allergy, for which no standardized diagnostic tests are available. Food challenges need to be performed in these cases to confirm clinical reactivity to the food(s) in question and prevent malnutrition from inappropriate food avoidance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical reactivity can be confirmed by double-blind, placebo-controlled food challenge (DBPCFC) for suspected IgE-mediated allergy or reproducible findings upon elimination and reintroduction of the food for suspected non-IgE mediated allergy. There is a risk of a more severe reaction, including anaphylaxis, when foods are reintroduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/34\">",
"     34",
"    </a>",
"    ]. The rate of food-exacerbated AD varies with the severity of the eczema. Approximately 1 to 3 percent of children with mild AD, 5 to 10 percent with moderate AD, and 20 to 33 percent with severe AD have food-induced AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/35\">",
"     35",
"    </a>",
"    ]. Food-exacerbated AD is rare in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subset of patients with AD (22 percent) was identified in a birth cohort of 512 children followed until two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/31\">",
"       31",
"      </a>",
"      ]. The children with AD were evaluated for food allergy. Food allergy was diagnosed based upon a history of an immediate reaction to a food allergen and a positive skin prick",
"      <span class=\"nowrap\">",
"       test/specific",
"      </span>",
"      serum IgE or a history of suspected food allergy with no immediate reaction and either an open",
"      <span class=\"nowrap\">",
"       elimination/challenge",
"      </span>",
"      test (performed twice, considered allergic if positive both times) or DBPCFC.",
"      <br/>",
"      <br/>",
"      Thirty-two percent of children in the above study were sensitized to at least one allergen [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/31\">",
"       31",
"      </a>",
"      ]. However, clinical reactivity was confirmed in only 18 percent. Two children developed AD after they had developed tolerance to the food. The rest of the children (16 percent) developed AD and adverse reactions to food simultaneously and were considered to have food-exacerbated AD. Six children had non-IgE mediated cow's milk allergy only. Eight children had IgE-mediated food allergy. The mean SCORAD index, a measure of AD severity, was higher in children with non-IgE or IgE-mediated food allergy than children without food allergy (28 and 30 versus 20, respectively).",
"     </li>",
"     <li>",
"      Other studies have reported similar findings with regard to the frequency of food-induced AD reactions in relation to the severity of AD. Food allergies play a role in exacerbating AD in up to 33 percent of patients with severe AD, 10 to 20 percent with moderate AD, and 6 percent with mild AD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/4,8,36\">",
"       4,8,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another birth cohort study, 22 percent",
"      <span class=\"nowrap\">",
"       (122/562)",
"      </span>",
"      of children had AD. Fifteen percent",
"      <span class=\"nowrap\">",
"       (18/122)",
"      </span>",
"      were confirmed to have food allergy (by skin prick test, specific IgE, and food challenge). Most children were also sensitized to other foods that they tolerated. Self-reported food allergy was confirmed in less than one-third of cases.",
"     </li>",
"     <li>",
"      In a study of 3- to 15-year-old patients with AD and suspected food allergies, 75 percent",
"      <span class=\"nowrap\">",
"       (52/69)",
"      </span>",
"      had positive challenges (average two foods, range one to three), based upon comparing pre- and post-challenge photographs of representative skin lesion sites [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/37\">",
"       37",
"      </a>",
"      ]. Most patients had negative specific IgE to the challenge-positive foods. Exclusion of these foods from the diet for three months led to significant clinical improvement.",
"     </li>",
"     <li>",
"      A meta-analysis showing lack of benefit of exclusion diets in patients with AD is held up by some as evidence of lack of a role for food allergy in AD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/38\">",
"       38",
"      </a>",
"      ]. However, 9 out of 10 of the randomized trials in this meta-analysis enrolled patients with AD who were not selected for a suspicion of food allergy based upon clinical history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      test results. The single trial that did select for patients with suspected food allergy (positive specific IgE to egg and suspected egg allergy) demonstrated that an egg elimination diet led to improvements in the extent and severity of AD in half of infants with AD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Food elimination diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings above highlight that foods should not be eliminated from the diet randomly without firm clinical suspicion. Nor should foods be excluded from the diet long-term (as opposed to short-term for diagnostic purposes) based upon positive skin or in vitro tests or patient history alone.",
"   </p>",
"   <p>",
"    Test results should be correlated with the clinical history and clinical reactivity confirmed when necessary by DBPCFC or",
"    <span class=\"nowrap\">",
"     elimination/challenge",
"    </span>",
"    test. Elimination of food allergens in patients with AD and confirmed food allergy can lead to significant clinical improvement. Patients should be evaluated at regular intervals to determine if the food allergy has resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL ALLERGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are less data on the role of environmental allergies in AD, compared with food allergies. The data available suggest that environmental allergens are a trigger of AD in a small subset of children and adults. Patients who have environmental allergies as a trigger of AD have persistent disease with chronic exposure to an allergen in the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aeroallergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to aeroallergens may occur by inhalation or by direct skin contact.",
"   </p>",
"   <p>",
"    There are several lines of evidence that support the concept that immune responses in AD skin can be elicited by aeroallergens in sensitized patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of schoolchildren, sensitization to aeroallergens, particularly cat and dust mite, correlated with disease severity [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/39\">",
"       39",
"      </a>",
"      ]. These children had persistent AD on areas of exposure (eg, on areas of their arms not covered by a shirt).",
"     </li>",
"     <li>",
"      Atopy patch tests (APT) to aeroallergens elicit delayed type eczematous reactions on uninvolved skin in 40 to 85 percent of patients with AD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/22,40-44\">",
"       22,40-44",
"      </a>",
"      ]. Rates of positive APT are generally lower in young children with mild AD and higher in older children and adults with moderate-to-severe AD. Positive APT reactions are also more frequent in patients that have AD in an air-exposed distribution pattern. However, APT results do not always correlate with disease extent, severity, or localization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/44\">",
"       44",
"      </a>",
"      ]. Dust mites are consistently the most common positive aeroallergen, and also appear to be the most clinically relevant [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"       \"Future diagnostic tools for food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intranasal and bronchial challenges with aeroallergens cause pruritus and flare up of AD lesions in some patients with AD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Effective measures to reduce house dust mite allergen improve AD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T cells that selectively respond to Dermatophagoides pteronyssinus (Der p 1) and other aeroallergens have been isolated from AD skin lesions and allergen patch test sites [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional line of evidence in support of the role of environmental allergies in AD is that therapies used for other atopic diseases are also effective in AD. Dust mite subcutaneous immunotherapy in adults with chronic moderate AD improved eczema severity scores (SCORAD) and reduced use of topical glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Anti-IgE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) therapy improved AD in patients with concomitant asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link\">",
"     \"Management of severe refractory atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Malassezia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malassezia yeast is part of the normal cutaneous microflora, and is found predominantly in lipid-rich areas, such as the head and neck. Immune reactions, both IgE and T cell-mediated, to Malassezia species can also worsen AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26551/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. IgE specific to Malassezia has been found in adolescent and adult patients with refractory head and neck AD. These patients may respond to antifungal therapy (eg, a one to two month course of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    followed by long-term weekly treatment). In addition, topical calcineurin inhibitors may inhibit the growth of Malassezia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there has been some controversy with regard to the role of allergy in atopic dermatitis (eczema), the bulk of the data indicate that allergy plays a role in selected patients with AD. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and young children with AD are more commonly sensitized to foods, whereas children over five years and adults are more commonly sensitized to aeroallergens. However, evidence of allergen sensitization is not proof of clinically relevant allergy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Allergen sensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with AD, the rate of sensitization to foods (positive skin or in vitro test) ranges from 30 to 80 percent, depending upon the population. The rate of confirmed food allergy is much lower. Food allergies play a role in exacerbating AD in up to 33 percent of patients with severe AD, 10 to 20 percent with moderate AD, and 6 percent with mild AD. Elimination of food allergens in patients with AD and confirmed food allergy can lead to significant clinical improvement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Food allergies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foods should not be eliminated from the diet randomly without any clinical suspicion. Nor should foods be excluded from the diet long-term (as opposed to short-term for diagnostic purposes) based upon positive skin or in vitro tests or patient history alone. Test results should be correlated with the clinical history and clinical reactivity confirmed when necessary by double-blind, placebo-controlled food challenge, or",
"      <span class=\"nowrap\">",
"       elimination/challenge",
"      </span>",
"      test. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Food elimination diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The data on the role of aeroallergens in exacerbating AD are less extensive. Dust mites are consistently the most common positive aeroallergen, and also appear to be the most clinically relevant. Immune reactions, both IgE and T cell-mediated, to Malassezia species can also worsen AD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Environmental allergies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/1\">",
"      Caubet JC, Eigenmann PA. Allergic triggers in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/2\">",
"      Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003; 111:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/3\">",
"      Naldi L, Parazzini F, Gallus S, GISED Study Centres. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. Acta Derm Venereol 2009; 89:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/4\">",
"      Eigenmann PA, Calza AM. Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis. Pediatr Allergy Immunol 2000; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/5\">",
"      Garc&iacute;a C, El-Qutob D, Martorell A, et al. Sensitization in early age to food allergens in children with atopic dermatitis. Allergol Immunopathol (Madr) 2007; 35:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/6\">",
"      Kanny G, Moneret-Vautrin DA, Flabbee J, et al. Population study of food allergy in France. J Allergy Clin Immunol 2001; 108:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/7\">",
"      Woods RK, Thien F, Raven J, et al. Prevalence of food allergies in young adults and their relationship to asthma, nasal allergies, and eczema. Ann Allergy Asthma Immunol 2002; 88:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/8\">",
"      Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/9\">",
"      Sampson HA. The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/10\">",
"      Burks AW, James JM, Hiegel A, et al. Atopic dermatitis and food hypersensitivity reactions. J Pediatr 1998; 132:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/11\">",
"      Niggemann B, Sielaff B, Beyer K, et al. Outcome of double-blind, placebo-controlled food challenge tests in 107 children with atopic dermatitis. Clin Exp Allergy 1999; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/12\">",
"      Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004; 34:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/13\">",
"      Hill DJ, Hosking CS, de Benedictis FM, et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 2008; 38:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/14\">",
"      Horwitz AA, Hossain J, Yousef E. Correlates of outcome for atopic dermatitis. Ann Allergy Asthma Immunol 2009; 103:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/15\">",
"      Fukiwake N, Furusyo N, Takeoka H, et al. Association factors for atopic dermatitis in nursery school children in Ishigaki islands - Kyushu University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol 2008; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/16\">",
"      Zitnik SE, R&uuml;schendorf F, M&uuml;ller S, et al. IL13 variants are associated with total serum IgE and early sensitization to food allergens in children with atopic dermatitis. Pediatr Allergy Immunol 2009; 20:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/17\">",
"      Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol 2008; 35:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/18\">",
"      Sch&auml;fer T. The impact of allergy on atopic eczema from data from epidemiological studies. Curr Opin Allergy Clin Immunol 2008; 8:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/19\">",
"      Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004; 114:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/20\">",
"      Eller E, Kjaer HF, H&oslash;st A, et al. Food allergy and food sensitization in early childhood: results from the DARC cohort. Allergy 2009; 64:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/21\">",
"      Hon KL, Leung TF, Ching G, et al. Patterns of food and aeroallergen sensitization in childhood eczema. Acta Paediatr 2008; 97:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/22\">",
"      P&oacute;nyai G, Hidv&eacute;gi B, N&eacute;meth I, et al. Contact and aeroallergens in adulthood atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/23\">",
"      Fuiano N, Fusilli S, Incorvaia C. House dust mite-related allergic diseases: role of skin prick test, atopy patch test, and RAST in the diagnosis of different manifestations of allergy. Eur J Pediatr 2010; 169:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/24\">",
"      Flohr C, Weiland SK, Weinmayr G, et al. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol 2008; 121:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/25\">",
"      Sch&auml;fer T, Kr&auml;mer U, Vieluf D, et al. The excess of atopic eczema in East Germany is related to the intrinsic type. Br J Dermatol 2000; 143:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/26\">",
"      de Benedictis FM, Franceschini F, Hill D, et al. The allergic sensitization in infants with atopic eczema from different countries. Allergy 2009; 64:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/27\">",
"      Werfel T, Breuer K. Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 2004; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/28\">",
"      Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/29\">",
"      Ranc&eacute; F. Food allergy in children suffering from atopic eczema. Pediatr Allergy Immunol 2008; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/30\">",
"      Noh G, Jin H, Lee J, et al. Eosinophilia as a predictor of food allergy in atopic dermatitis. Allergy Asthma Proc 2010; 31:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/31\">",
"      Kvenshagen B, Jacobsen M, Halvorsen R. Atopic dermatitis in premature and term children. Arch Dis Child 2009; 94:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/32\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/33\">",
"      Sampson HA. Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol 1999; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/34\">",
"      Spergel JM, Beausoleil JL, Fiedler JM, et al. Correlation of initial food reactions to observed reactions on challenges. Ann Allergy Asthma Immunol 2004; 92:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/35\">",
"      Forbes LR, Saltzman RW, Spergel JM. Food allergies and atopic dermatitis: differentiating myth from reality. Pediatr Ann 2009; 38:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/36\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/37\">",
"      Uenishi T, Sugiura H, Tanaka T, Uehara M. Role of foods in irregular aggravation of skin lesions in children with atopic dermatitis. J Dermatol 2008; 35:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/38\">",
"      Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev 2008; :CD005203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/39\">",
"      Sch&auml;fer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999; 104:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/40\">",
"      Ring J, Darsow U, Gfesser M, Vieluf D. The 'atopy patch test' in evaluating the role of aeroallergens in atopic eczema. Int Arch Allergy Immunol 1997; 113:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/41\">",
"      Devillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Atopy patch tests with aeroallergens in children aged 0-3 years with atopic dermatitis. Allergy 2008; 63:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/42\">",
"      Boralevi F, Hubiche T, L&eacute;aut&eacute;-Labr&egrave;ze C, et al. Epicutaneous aeroallergen sensitization in atopic dermatitis infants - determining the role of epidermal barrier impairment. Allergy 2008; 63:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/43\">",
"      Samochocki Z, Owczarek W, Rujna P, Raczka A. Hypersensitivity to aeroallergens in adult patients with atopic dermatitis develops due to the different immunological mechanisms. Eur J Dermatol 2007; 17:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/44\">",
"      Czarnecka-Operacz M, Bator-Wegner M, Silny W. Atopy patch test reaction to airborne allergens in the diagnosis of atopic dermatitis. Acta Dermatovenerol Croat 2005; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/45\">",
"      Brinkman L, Aslander MM, Raaijmakers JA, et al. Bronchial and cutaneous responses in atopic dermatitis patients after allergen inhalation challenge. Clin Exp Allergy 1997; 27:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/46\">",
"      Tupker RA, De Monchy JG, Coenraads PJ, et al. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996; 97:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/47\">",
"      Reekers R, Busche M, Wittmann M, et al. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol 1999; 104:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/48\">",
"      Sager N, Feldmann A, Schilling G, et al. House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992; 89:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/49\">",
"      Wakugawa M, Hayashi K, Nakamura K, Tamaki K. Evaluation of mite allergen-induced Th1 and Th2 cytokine secretion of peripheral blood mononuclear cells from atopic dermatitis patients: association between IL-13 and mite-specific IgE levels. J Dermatol Sci 2001; 25:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/50\">",
"      Werfel T, Breuer K, Ru&eacute;ff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/51\">",
"      Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/52\">",
"      Belloni B, Andres C, Ollert M, et al. Novel immunological approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol 2008; 8:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/53\">",
"      Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/54\">",
"      Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/55\">",
"      Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009; 60:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26551/abstract/56\">",
"      Vilhelmsson M, Glaser AG, Martinez DB, et al. Mutational analysis of amino acid residues involved in IgE-binding to the Malassezia sympodialis allergen Mala s 11. Mol Immunol 2008; 46:294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5545 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26551=[""].join("\n");
var outline_f25_59_26551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATOPIC ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALLERGEN SENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FOOD ALLERGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Food elimination diets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ENVIRONMENTAL ALLERGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aeroallergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Malassezia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=related_link\">",
"      Nutritional issues in food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26552="Immunopathogenesis of Lyme disease";
var content_f25_59_26552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunopathogenesis of Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26552/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/59/26552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H543913165\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the understanding of the interactions that occur between B. burgdorferi and its mammalian and tick hosts have led to important insights into the pathogenic mechanisms that underlie the manifestations of human Lyme disease. With the sequencing of the B. burgdorferi genome came several surprising insights. Among these is the fact that B. burgdorferi has a very small genome compared with other bacteria. It does not encode for any toxins or lipopolysaccharides, but does encode a large number of lipoproteins relative to other bacteria. Also missing from its genome are genes that enable bacteria to synthesize such essential products as amino acids, fatty acids, enzyme cofactors, and nucleotides. As such, B. burgdorferi is dependent upon its environment to provide these nutrients and has evolved specialized mechanisms for adapting to its different environments.",
"   </p>",
"   <p>",
"    The lifecycle of B. burgdorferi requires that it survive in two distinct environments &mdash; that found in a tick host and that found in a mammalian host. The challenges posed by these environments differ greatly. Because ticks do not thermoregulate, while in the tick host B. burgdorferi must survive at the extremes of ambient temperatures found in winter and summer in its areas of geographic distribution. In addition, ticks take only one blood meal every 6 to 12 months, and as a result, B. burgdorferi must be able to survive with minimal nutrition for long periods of time.",
"   </p>",
"   <p>",
"    In contrast, life in a mammalian host provides a stable temperature and an abundance of nutrients. However, compared with ticks, which have rudimentary immune systems, mammals have highly sophisticated immune defenses. The ability of B. burgdorferi to cause long-term infection in mammalian hosts requires that it implement strategies to successfully evade and subvert host immune defenses. Optimal host immune control of B. burgdorferi infection requires both innate and adaptive immune systems. However, neither system, alone or in combination, is able to completely eradicate the organism in mice despite resolution of signs of infection and inflammation. In humans, it appears that the immune system can eventually eradicate the infection, since almost all patients eventually resolve their symptoms even without antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/1\">",
"     1",
"    </a>",
"    ]. In Europe, B. afzelii has been cultured from skin lesions of patients in Europe with acrodermatitis atrophicans after greater than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/2\">",
"     2",
"    </a>",
"    ], but this genotype is not present in the United States.",
"   </p>",
"   <p>",
"    In this topic, we will describe some of the mechanisms that B. burgdorferi uses to establish infection as well as the host immune responses to invasion by the organism that both help control the infection and also cause some of the manifestations of Lyme disease. The microbiology, epidemiology, clinical manifestations, diagnosis, prevention, and treatment of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"     \"Evaluation of a tick bite for possible Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913275\">",
"    <span class=\"h1\">",
"     ACUTE LOCALIZED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913283\">",
"    <span class=\"h2\">",
"     Bacterial adaptations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H489178\">",
"    <span class=\"h3\">",
"     Outer surface protein variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. burgdorferi exit the tick while it feeds on a mammalian host and establish infection in the skin. To transit from the tick midgut, where the B. burgdorferi are located prior to initiation of feeding, to the tick salivary gland, the organism rapidly downregulates a protein called outer surface protein A (OspA) and upregulates another protein called outer surface protein C (OspC) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Downregulation of OspA accomplishes two tasks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since OspA is involved in the binding to the tick midgut, downregulation facilitates detachment from the midgut and transit to the salivary glands",
"     </li>",
"     <li>",
"      Downregulation of OspA removes a potent target for the immune system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OspA was used as the antigen in the human Lyme disease vaccine, which is no longer available, and antibodies to OspA efficiently target and kill bacteria expressing this protein [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of Lyme disease\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upregulation of OspC facilitates invasion of bacteria into skin, and, in the absence of OspC, bacteria are unable to establish infection in the mammalian host efficiently [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], although it is possible that other proteins may substitute for the function of OspC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/11\">",
"     11",
"    </a>",
"    ]. One role for OspC is in the binding of a tick salivary protein, Salp15. Binding of Salp15 may protect the spirochete by inhibiting antibody-mediated killing. Salp15 also inhibits activation of T lymphocytes by binding to the CD4 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that not all B. burgdorferi in the population turn off OspA and turn on OspC as the tick takes its blood meal. Studies have shown that there is heterogeneity in protein expression, likely due to differences in either the microenvironments encountered by the bacteria, slow turnover of proteins, or subtle genetic differences between the bacteria themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H489185\">",
"    <span class=\"h2\">",
"     Factors in tick saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick saliva contains several factors that are important in altering the host inflammatory response, which is important for the tick to feed successfully, but may also be exploited by B. burgdorferi to establish infection. Induction of Th1 type, pro-inflammatory cytokines has been shown to improve early host control of borrelial infection, whereas induction of Th2 type cytokine responses are more permissive for the establishment of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Tick saliva has been shown to promote the release of Th2 type cytokines (eg, interleukin 4 and 10) that suppress cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Tick saliva also contains components that can inactivate antimicrobial peptide release, chemotaxis of neutrophils, complement activation and the generation of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913290\">",
"    <span class=\"h2\">",
"     Host response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest host immune responses to the entry of B. burgdorferi into the skin are from the innate immune system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490037\">",
"    <span class=\"h3\">",
"     Cellular immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. burgdorferi is effectively killed by professional phagocytes such as neutrophils and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In animal models, there is early recruitment of neutrophils and basophils to the site of inoculation, but this is rapidly replaced by eosinophils and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/26\">",
"     26",
"    </a>",
"    ]. Histologic examinations of human erythema migrans lesions show a marked lack of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/27\">",
"     27",
"    </a>",
"    ]. Artificially increasing the number of neutrophils infiltrating an erythema migrans lesion by increasing amounts of neutrophil chemokines in the lesion may improve early control of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/26\">",
"     26",
"    </a>",
"    ], but it is unknown whether Borrelia specifically suppress neutrophil infiltration as a mechanism of immune evasion. Two tick salivary proteins have been shown to suppress neutrophil adherence and killing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/19\">",
"     19",
"    </a>",
"    ]. Recognition and processing of B. burgdorferi by macrophages and dendritic cells result in release of cytokines and recruitment of T cells and B cells to the site of infection. Induction of cytokines and chemokines occurs largely through recognition by pattern recognition receptors (PRRs) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490030\">",
"    <span class=\"h3\">",
"     Toll-like receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate immune effector cells such as neutrophils and macrophages recognize pathogens through identification of pathogen associated molecular products (PAMPs) by pattern recognition receptors PRRs. Among the best studied PRRs are the toll-like receptors (TLRs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The human genome encodes for 10 known TLRs, each of which recognize specific microbial products (eg, lipopolysaccharide, microbial DNA, peptidoglycan). Borrelial lipoproteins are recognized by heterodimers of TLR1 and TLR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Engagement of",
"    <span class=\"nowrap\">",
"     TLR1/TLR2",
"    </span>",
"    by borrelial lipoproteins results in activation of multiple downstream signaling pathways as well as translocation of nuclear factor kappa B (NFkB), leading to the release of inflammatory cytokines and chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/30\">",
"     30",
"    </a>",
"    ]. Among the chemokines and cytokines found to be elevated in erythema migrans lesions are interleukin (IL)-6, interferon-gamma, IL-1b, tumor necrosis factor-alpha (TNF-alpha), IL-12 and transforming growth factor-beta (TGF-beta) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/27,32\">",
"     27,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with the histological findings in erythema migrans, levels of the macrophage and T cell chemokines are increased over neutrophil chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. In animal models, TLRs have been shown to play an important role in controlling infection with B. burgdorferi, but TLR-deficient animals show high levels of inflammation and cytokine release, suggesting that there are redundant pathways for detecting Borrelia and activating inflammatory pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TLR1 and TLR2 may also affect B. burgdorferi gene expression. A microarray analysis of B. burgdorferi gene expression in a mouse model showed that several genes were altered in",
"    <span class=\"nowrap\">",
"     TLR1/2-deficient",
"    </span>",
"    mice compared with wild-type mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/37\">",
"     37",
"    </a>",
"    ]. This suggests that B. burgdorferi may be altering protein expression in response to the inflammatory environment mediated by TLR signaling. It is currently unknown how the genes that have been identified as altered in",
"    <span class=\"nowrap\">",
"     TLR1/2-deficient",
"    </span>",
"    mice are involved in the adaptation to either the wild-type or the",
"    <span class=\"nowrap\">",
"     TLR1/2-deficient",
"    </span>",
"    milieu.",
"   </p>",
"   <p>",
"    TLR signaling may also play an important role in phagocytosis of Borrelia, antigen presentation, and the subsequent development of an adaptive immune response to the organism. Other receptors that may be important in the early recognition of Borrelia and induction of inflammatory mediators include integrin-type receptors such as complement receptor 3 (CR3) and integrin alpha(3)beta(1) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913298\">",
"    <span class=\"h1\">",
"     ACUTE DISSEMINATED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913306\">",
"    <span class=\"h2\">",
"     Bacterial adaptations",
"    </span>",
"    &nbsp;&mdash;&nbsp;After inoculation into the skin, Borrelia begins to multiply rapidly. Dissemination to distant sites begins to occur within two to three days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. It appears that some strains of Borrelia are more prone to dissemination than others, although this remains controversial and the specific mechanisms involved remain unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/43\">",
"     43",
"    </a>",
"    ]. Other studies have shown that the distribution of subtypes in distal tissues is similar to the distribution of subtypes in skin, suggesting that the differences in the presence of subtypes in blood may be due to the ability to detect these strains in blood and not to differences in the capacity for dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14911859\">",
"    <span class=\"h3\">",
"     Adherence to host cells and ECM proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early phase of infection after inoculation, B. burgdorferi use several different strategies to establish infection and disseminate. Adherence to host cells and extracellular matrix proteins is an important first step in the establishment of infection. B. burgdorferi expresses proteins that bind to host integrins, proteoglycans and glycoproteins. Among the identified proteins are P66, BBK32, and decorin binding protein. P66 is a borrelial protein that binds to integrin receptors such as integrin alpha(IIB)beta(3), which is expressed on platelets and which may facilitate dissemination of the bacteria on entry into the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. BBK32 and decorin binding protein adhere to fibronectin and decorin, respectively; these proteins are found in the extracellular matrix of tissues where Borrelia have a predilection to disseminate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Bacteria that have deletions of BBK32 or decorin binding protein have defects in their ability to establish infection and to colonize distant tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Binding to decorin may protect the organism from clearance by both the early innate immune response and the adaptive immune response. Whether variation in the sequence of these binding proteins between species of Borrelia accounts for differences in the frequency of specific clinical manifestations among strains of B. burgdorferi sensu lato has not yet been closely examined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490215\">",
"    <span class=\"h3\">",
"     Utilization of host proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to disseminate from the site of inoculation, Borrelia need to be able to move through the dense extracellular matrix of the skin and other tissues. Most other bacteria that are inoculated into skin and disseminate produce proteases capable of digesting extracellular matrix proteins. B. burgdorferi does not produce any known exported proteases capable of digesting extracellular matrix proteins. Instead, it appears to utilize host proteins for this function. B. burgdorferi bind plasmin, a serine protease capable of digesting many extracellular matrix components. In animal models, binding of plasmin has been shown to aid in the movement of B. burgdorferi into the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, plasmin is an activator of some matrix metalloproteinases. Matrix metalloproteinases are host proteases that are induced as part of the inflammatory response to Borrelia infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/53\">",
"     53",
"    </a>",
"    ]. As a family, matrix metalloproteinases can degrade every component of the extracellular matrix and are the major proteases capable of digesting collagen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14911866\">",
"    <span class=\"h3\">",
"     Evasion of antibody-mediated killing",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early phase after inoculation, the organism must begin to evade additional components of the immune system. IgM antibodies to prominent borrelial surface proteins, including outer surface protein C (OspC) and flagellin, begin to develop very early in infection. Antibodies against OspC, but not flagellin, are capable of killing the spirochete. While OspC is critical for the early establishment of infection, it is no longer necessary after the initial inoculation and is rapidly downregulated to evade antibody-mediated killing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/10,54\">",
"     10,54",
"    </a>",
"    ]. Bacteria that do not downregulate OspC are likely rapidly selected against. Another antigenic target, a surface lipoprotein called VlsE, is able to undergo antigenic variation during infection by recombination of 15 silent gene cassettes into the central expressed cassette to escape antibody-mediated killing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14911873\">",
"    <span class=\"h3\">",
"     Evasion of complement-mediated killing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement-mediated killing of Borrelia can occur either with or without the presence of specific antibody to B. burgdorferi, via the classical pathway or alternative pathway, respectively. To evade complement-mediated killing, Borrelia contain multiple proteins including outer surface protein E (OspE)-related proteins (Erps) and complement regulator-acquiring surface proteins (CRASPs) that bind complement factor H and complement factor H-like protein 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Factor H and factor H-like protein 1 bind and inactivate C3b and protect the organism from complement-mediated killing. The different strains of Borrelia express different variants of CRASPs and Erps that bind to Factor H from different species of mammals with varying efficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/58\">",
"     58",
"    </a>",
"    ]. It remains controversial whether these differences account for the predilection of certain species of Borrelia for particular mammalian hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913313\">",
"    <span class=\"h2\">",
"     Host response",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the early host response involves recognition by pattern recognition receptors, phagocytosis by macrophages and dendritic cells, and complement-mediated lysis. Each of these contributes to the control of infection, but ultimately, is not able to contain infection. As the organisms multiply and disseminate, it is presumed that the increased activation of immune effector cells and the release of inflammatory cytokines and pyrogens result in many of the non-specific signs of Lyme disease during this period including fevers, myalgias, and arthralgias. In animal models, localized findings, such as carditis, that occur during the acute disseminated phase are directly correlated with local levels of cytokines and often, but not always (depending upon the animal model), with the number of bacteria present in the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490044\">",
"    <span class=\"h3\">",
"     Cellular immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of specific types of cells in the development of local inflammation in response to Borrelia has been examined extensively in mouse models. While not all strains of mice develop significant pathology following infection with B. burgdorferi (eg, inbred",
"    <span class=\"nowrap\">",
"     C57BL/6",
"    </span>",
"    mice or the wild host Peromyscus mice), some strains such as inbred C3H mice develop carditis and arthritis after infection with the organism. Although arthritis is considered a manifestation of late disseminated disease, many of the immune processes are similar between arthritis and carditis, so the impact of the host immune system on these manifestations will be discussed together. The genes that control the severity of the response in different mouse strains have not been identified to date, although several loci on chromosomes have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/59\">",
"     59",
"    </a>",
"    ]. There are two major identifiable effects of the immune response during this stage &mdash; the generation of inflammation and the control of infection. Although the two are linked (ie, there is no inflammation in the absence of infection and conversely failure to control infection can overcome genetic resistance to the development of arthritis), different cells and different processes can contribute to each.",
"   </p>",
"   <p>",
"    Bacteria that have been phagocytized by macrophages or dendritic cells are processed and presented to CD4+ T helper cells. Depending upon the genetics of the mouse, these activated T cells may produce Th1 type responses where interferon-gamma is generated or Th2 type responses that generate anti-inflammatory cytokines such as IL-10. Mice of different genetic backgrounds are predisposed to generate either Th1 or Th2 type responses to infections with different pathogens. In general, Th1 type responses result in increased inflammation, but better control of infection whereas Th2 type responses suppress inflammation at the cost of control of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/13,60\">",
"     13,60",
"    </a>",
"    ]. Human T cell responses do not differentiate along the lines of Th1 and Th2 type responses as clearly as mice. CD4 cells in human peripheral blood and synovial fluid from patients with Lyme arthritis contain mixed populations of Th1, Th2, Th17, and Treg cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/61\">",
"     61",
"    </a>",
"    ]. In general, in mice both Th1 and Th2 type cytokines may be induced by infection with Borrelia. This is true even in mice with more differentiated Th1 and Th2 type responses and it is the relative balance between pro- and anti-inflammatory cytokines that determines the phenotype of the infection.",
"   </p>",
"   <p>",
"    Using the mouse model, the importance of specific cell types to control of inflammation and to control of infection has been delineated. Natural killer T cells are activated by diacylglycerol, a borrelial glycolipid, presented by CD1d-expressing cells such as macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/62\">",
"     62",
"    </a>",
"    ]. Mice with a beige mutation, which results in a lack of natural killer cells and impaired macrophage function, develop more severe arthritis during the early period, but resolve their symptoms in a time course similar to wild-type congenic mice, suggesting that there is still development of a normal adaptive immune response that clears the organism.",
"   </p>",
"   <p>",
"    Both adaptive T and B cell responses contribute to the control of infection, as severe combined immunodeficiency (SCID) mice or",
"    <span class=\"nowrap\">",
"     Rag-/-",
"    </span>",
"    mice, which lack both T and B cells have high tissue levels of bacteria following infection. On an arthritis-susceptible genetic background (eg, C3H), the absence of T and B cells leads to severe arthritis. However, on a resistant background (eg,",
"    <span class=\"nowrap\">",
"     C57BL/6),",
"    </span>",
"    the loss of T and B cells results in only minimal to moderate arthritis despite higher tissue numbers of bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Mice with a deletion of B cells but not T cells develop more severe arthritis and T and B cell depleted mice reconstituted with T cells alone also develop more severe arthritis, confirming a role for T cell in mediating inflammation that is separate from the control of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/64\">",
"     64",
"    </a>",
"    ]. B cells play a major role in clearing of infection but do not affect inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913321\">",
"    <span class=\"h1\">",
"     LATE DISSEMINATED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913329\">",
"    <span class=\"h2\">",
"     Bacterial adaptations",
"    </span>",
"    &nbsp;&mdash;&nbsp;During untreated late stage infection in mammals, symptoms persist at specific sites (joints, central nervous system), and it is suspected that B. burgdorferi may persist at low levels in these tissues. In untreated patients, B. burgdorferi has been cultured (rarely) from acrodermatitis lesions greater than 10 years after infection, and B. burgdorferi DNA can be amplified by PCR from synovial fluid for years after the onset of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The sites in which B. burgdorferi are found during late stage disease may be influenced by the species of B. burgdorferi (eg, B. burgdorferi sensu stricto in the US may be found in the joints, but is not found in the skin, whereas B. afzelii in Europe may be found in the skin). In mouse models, during late stage disease, the bacteria have typically downregulated most of the outer surface lipoproteins that serve as strong antigenic targets. Intermittent flares of arthritis occur in both untreated humans and mice, suggesting that the spirochetes become recognized by the host immune system. It is not clear what the cause of these flares are, but the potential hypotheses would include escape from immune control (eg, through antigenic variation by VlsE), allowing increased replication of the bacteria and reactivation of inflammation through stimulation of innate immune mechanisms. Another possibility is that B. burgdorferi express a new antigenic target in the presence of a specific stimuli that results in recognition by the immune system. In the wild mouse host, Borrelia must be able to sense and successfully colonize new feeding ticks in order to complete its lifecycle. It may sense and utilize tick salivary factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/19,67\">",
"     19,67",
"    </a>",
"    ] or inflammation in response to tick bites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/68\">",
"     68",
"    </a>",
"    ] to help facilitate re-entry into a tick, and it is possible that some of these triggering mechanisms may be responsible for activating expression of repressed proteins, such as OspA, that result in increased inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913337\">",
"    <span class=\"h2\">",
"     Host response",
"    </span>",
"    &nbsp;&mdash;&nbsp;During late stage disease, the adaptive immune system is typically successful at greatly reducing the bacterial numbers in tissues. With these reduced numbers of bacteria, activation of innate and adaptive immune mechanisms that release inflammatory cytokines systemically is reduced, although local levels may remain quite high. As a result, systemic symptoms are typically minimal during late infection. Low level destruction of tissue may continue to occur at sites where the bacteria are localized. The slow destruction of tissue compared with other bacterial causes of arthritis or encephalopathy likely is due to the low bacterial numbers and the fact that Borrelia, unlike other bacteria that spread through skin and cause end organ tissue damage, do not produce proteases capable of destroying host tissues and extracellular matrix. The damage that is seen is likely due to host inflammatory factors, including induced proteases such as matrix metalloproteinases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H490085\">",
"    <span class=\"h3\">",
"     Antibody response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that Borrelia typically downregulate outer surface proteins during mammalian infection, patients with late stage arthritis typically develop a very broad antibody response to many antigens, including to outer surface protein A [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/70\">",
"     70",
"    </a>",
"    ]. As a result, patients with Lyme arthritis are relatively resistant to reinfection with B. burgdorferi after antibiotic therapy, whereas those treated during earlier stages typically are not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/71\">",
"     71",
"    </a>",
"    ]. Although antibodies that develop early to proteins expressed during early infection such as outer surface protein C (OspC) are effective against the identical strain, sequence variation in OspC between strains make antibodies to OspC relatively non-protective against reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26552/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. In contrast, the sequence of OspA is relatively stable among North American strains of B. burgdorferi and antibodies to OspA are cross-protective against most strains found in the United States. Antibodies to OspA protect by entering into the tick midgut with the blood meal while OspA is still being expressed, and killing bacteria within the tick before it has a chance to enter the mammalian host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543913345\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Borrelia burgdorferi has evolved sophisticated mechanisms for adapting to its tick and mammalian hosts including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tight control of protein expression to minimize antigenic targets for immune recognition and",
"     </li>",
"     <li>",
"      Subversion of host mechanisms to establish infection and evade host immunity (See",
"      <a class=\"local\" href=\"#H543913165\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal host immune control of B. burgdorferi infection requires both innate and adaptive immune systems. &nbsp;(See",
"      <a class=\"local\" href=\"#H543913290\">",
"       'Host response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H543913313\">",
"       'Host response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H543913337\">",
"       'Host response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because B. burgdorferi do not produce toxins, proteases, or other destructive molecules, the majority of the symptoms seen with human Lyme disease are due to the effects of the host immune response. (See",
"      <a class=\"local\" href=\"#H543913290\">",
"       'Host response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H543913313\">",
"       'Host response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H543913337\">",
"       'Host response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/1\">",
"      Kalish RA, Kaplan RF, Taylor E, et al. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis 2001; 183:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/2\">",
"      Asbrink E. Erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Early and late manifestations of Ixodes ricinus-borne Borrelia spirochetes. Acta Derm Venereol Suppl (Stockh) 1985; 118:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/3\">",
"      Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J Clin Microbiol 2000; 38:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/4\">",
"      Srivastava SY, de Silva AM. Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi. J Bacteriol 2008; 190:3429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/5\">",
"      Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 1992; 60:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/6\">",
"      Fikrig E, Telford SR 3rd, Barthold SW, et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci U S A 1992; 89:5418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/7\">",
"      Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 1998; 339:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/8\">",
"      Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/9\">",
"      Ramamoorthi N, Narasimhan S, Pal U, et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 2005; 436:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/10\">",
"      Grimm D, Tilly K, Byram R, et al. Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proc Natl Acad Sci U S A 2004; 101:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/11\">",
"      Xu Q, McShan K, Liang FT. Essential protective role attributed to the surface lipoproteins of Borrelia burgdorferi against innate defences. Mol Microbiol 2008; 69:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/12\">",
"      Anguita J, Ramamoorthi N, Hovius JW, et al. Salp15, an ixodes scapularis salivary protein, inhibits CD4(+) T cell activation. Immunity 2002; 16:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/13\">",
"      Brown JP, Zachary JF, Teuscher C, et al. Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense. Infect Immun 1999; 67:5142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/14\">",
"      Schaible UE, Kramer MD, Wallich R, et al. Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol 1991; 21:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/15\">",
"      Keane-Myers A, Nickell SP. Role of IL-4 and IFN-gamma in modulation of immunity to Borrelia burgdorferi in mice. J Immunol 1995; 155:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/16\">",
"      Zeidner NS, Schneider BS, Rutherford JS, Dolan MC. Suppression of Th2 cytokines reduces tick-transmitted Borrelia burgdorferi load in mice. J Parasitol 2008; 94:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/17\">",
"      Brossard M, Wikel SK. Immunology of interactions between ticks and hosts. Med Vet Entomol 1997; 11:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/18\">",
"      Schoeler GB, Manweiler SA, Wikel SK. Ixodes scapularis: effects of repeated infestations with pathogen-free nymphs on macrophage and T lymphocyte cytokine responses of BALB/c and C3H/HeN mice. Exp Parasitol 1999; 92:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/19\">",
"      Guo X, Booth CJ, Paley MA, et al. Inhibition of neutrophil function by two tick salivary proteins. Infect Immun 2009; 77:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/20\">",
"      Tyson K, Elkins C, Patterson H, et al. Biochemical and functional characterization of Salp20, an Ixodes scapularis tick salivary protein that inhibits the complement pathway. Insect Mol Biol 2007; 16:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/21\">",
"      Marchal C, Schramm F, Kern A, et al. Antialarmin effect of tick saliva during the transmission of Lyme disease. Infect Immun 2011; 79:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/22\">",
"      Kotsyfakis M, S&aacute;-Nunes A, Francischetti IM, et al. Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem 2006; 281:26298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/23\">",
"      Lusitani D, Malawista SE, Montgomery RR. Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J Infect Dis 2002; 185:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/24\">",
"      Peterson PK, Clawson CC, Lee DA, et al. Human phagocyte interactions with the Lyme disease spirochete. Infect Immun 1984; 46:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/25\">",
"      Montgomery RR, Nathanson MH, Malawista SE. The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery. J Immunol 1993; 150:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/26\">",
"      Xu Q, Seemanapalli SV, Reif KE, et al. Increasing the recruitment of neutrophils to the site of infection dramatically attenuates Borrelia burgdorferi infectivity. J Immunol 2007; 178:5109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/27\">",
"      Salazar JC, Pope CD, Sellati TJ, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003; 171:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/28\">",
"      Salazar JC, Duhnam-Ems S, La Vake C, et al. Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and -independent responses which include induction of IFN-beta. PLoS Pathog 2009; 5:e1000444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/29\">",
"      Shin OS, Isberg RR, Akira S, et al. Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction. Infect Immun 2008; 76:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/30\">",
"      Hirschfeld M, Kirschning CJ, Schwandner R, et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/31\">",
"      Alexopoulou L, Thomas V, Schnare M, et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002; 8:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/32\">",
"      Jones KL, Muellegger RR, Means TK, et al. Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis. Clin Infect Dis 2008; 46:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/33\">",
"      M&uuml;llegger RR, Means TK, Shin JJ, et al. Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect Immun 2007; 75:4621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/34\">",
"      Wooten RM, Ma Y, Yoder RA, et al. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002; 168:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/35\">",
"      Liu N, Montgomery RR, Barthold SW, Bockenstedt LK. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice. Infect Immun 2004; 72:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/36\">",
"      Behera AK, Hildebrand E, Bronson RT, et al. MyD88 deficiency results in tissue-specific changes in cytokine induction and inflammation in interleukin-18-independent mice infected with Borrelia burgdorferi. Infect Immun 2006; 74:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/37\">",
"      Fikrig E, Narasimhan S, Neelakanta G, et al. Toll-like receptors 1 and 2 heterodimers alter Borrelia burgdorferi gene expression in mice and ticks. J Infect Dis 2009; 200:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/38\">",
"      Cinco M, Murgia R, Presani G, Perticarari S. Integrin CR3 mediates the binding of nonspecifically opsonized Borrelia burgdorferi to human phagocytes and mammalian cells. Infect Immun 1997; 65:4784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/39\">",
"      Behera AK, Durand E, Cugini C, et al. Borrelia burgdorferi BBB07 interaction with integrin alpha3beta1 stimulates production of pro-inflammatory mediators in primary human chondrocytes. Cell Microbiol 2008; 10:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/40\">",
"      Nadelman RB, Wormser GP. Erythema migrans and early Lyme disease. Am J Med 1995; 98:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/41\">",
"      Berger BW, Johnson RC, Kodner C, Coleman L. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992; 30:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/42\">",
"      Wormser GP, McKenna D, Carlin J, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/43\">",
"      Wormser GP, Brisson D, Liveris D, et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis 2008; 198:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/44\">",
"      Jones KL, McHugh GA, Glickstein LJ, Steere AC. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum 2009; 60:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/45\">",
"      Defoe G, Coburn J. Delineation of Borrelia burgdorferi p66 sequences required for integrin alpha(IIb)beta(3) recognition. Infect Immun 2001; 69:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/46\">",
"      Coburn J, Magoun L, Bodary SC, Leong JM. Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of lyme disease spirochetes to human cells. Infect Immun 1998; 66:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/47\">",
"      Fischer JR, LeBlanc KT, Leong JM. Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. Infect Immun 2006; 74:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/48\">",
"      Seshu J, Esteve-Gassent MD, Labandeira-Rey M, et al. Inactivation of the fibronectin-binding adhesin gene bbk32 significantly attenuates the infectivity potential of Borrelia burgdorferi. Mol Microbiol 2006; 59:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/49\">",
"      Weening EH, Parveen N, Trzeciakowski JP, et al. Borrelia burgdorferi lacking DbpBA exhibits an early survival defect during experimental infection. Infect Immun 2008; 76:5694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/50\">",
"      Shi Y, Xu Q, McShan K, Liang FT. Both decorin-binding proteins A and B are critical for the overall virulence of Borrelia burgdorferi. Infect Immun 2008; 76:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/51\">",
"      Shi Y, Xu Q, Seemanaplli SV, et al. Common and unique contributions of decorin-binding proteins A and B to the overall virulence of Borrelia burgdorferi. PLoS One 2008; 3:e3340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/52\">",
"      Coleman JL, Gebbia JA, Piesman J, et al. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997; 89:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/53\">",
"      Hu LT, Eskildsen MA, Masgala C, et al. Host metalloproteinases in Lyme arthritis. Arthritis Rheum 2001; 44:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/54\">",
"      Pal U, Yang X, Chen M, et al. OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands. J Clin Invest 2004; 113:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/55\">",
"      Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/56\">",
"      Hellwage J, Meri T, Heikkil&auml; T, et al. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J Biol Chem 2001; 276:8427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/57\">",
"      Kraiczy P, Skerka C, Brade V, Zipfel PF. Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun 2001; 69:7800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/58\">",
"      Stevenson B, El-Hage N, Hines MA, et al. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun 2002; 70:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/59\">",
"      Weis JJ, McCracken BA, Ma Y, et al. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease. J Immunol 1999; 162:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/60\">",
"      Lazarus JJ, Meadows MJ, Lintner RE, Wooten RM. IL-10 deficiency promotes increased Borrelia burgdorferi clearance predominantly through enhanced innate immune responses. J Immunol 2006; 177:7076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/61\">",
"      Shen S, Shin JJ, Strle K, et al. Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Arthritis Rheum 2010; 62:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/62\">",
"      Olson CM Jr, Bates TC, Izadi H, et al. Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J Immunol 2009; 182:3728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/63\">",
"      Brown CR, Reiner SL. Genetic control of experimental lyme arthritis in the absence of specific immunity. Infect Immun 1999; 67:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/64\">",
"      McKisic MD, Redmond WL, Barthold SW. Cutting edge: T cell-mediated pathology in murine Lyme borreliosis. J Immunol 2000; 164:6096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/65\">",
"      Asbrink E, Hovmark A. Successful cultivation of spirochetes from skin lesions of patients with erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Acta Pathol Microbiol Immunol Scand B 1985; 93:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/66\">",
"      Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/67\">",
"      Scheckelhoff MR, Telford SR, Wesley M, Hu LT. Borrelia burgdorferi intercepts host hormonal signals to regulate expression of outer surface protein A. Proc Natl Acad Sci U S A 2007; 104:7247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/68\">",
"      Crowley H, Huber BT. Host-adapted Borrelia burgdorferi in mice expresses OspA during inflammation. Infect Immun 2003; 71:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/69\">",
"      Lin B, Kidder JM, Noring R, et al. Differences in synovial fluid levels of matrix metalloproteinases suggest separate mechanisms of pathogenesis in Lyme arthritis before and after antibiotic treatment. J Infect Dis 2001; 184:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/70\">",
"      Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993; 61:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/71\">",
"      Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin Infect Dis 2007; 45:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/72\">",
"      Jauris-Heipke S, Fuchs R, Motz M, et al. Genetic heterogenity of the genes coding for the outer surface protein C (OspC) and the flagellin of Borrelia burgdorferi. Med Microbiol Immunol 1993; 182:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/73\">",
"      Theisen M, Frederiksen B, Lebech AM, et al. Polymorphism in ospC gene of Borrelia burgdorferi and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. J Clin Microbiol 1993; 31:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26552/abstract/74\">",
"      Probert WS, Crawford M, Cadiz RB, LeFebvre RB. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 1997; 175:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14008 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26552=[""].join("\n");
var outline_f25_59_26552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H543913345\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543913165\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543913275\">",
"      ACUTE LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913283\">",
"      Bacterial adaptations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H489178\">",
"      - Outer surface protein variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H489185\">",
"      Factors in tick saliva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913290\">",
"      Host response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H490037\">",
"      - Cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H490030\">",
"      - Toll-like receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543913298\">",
"      ACUTE DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913306\">",
"      Bacterial adaptations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14911859\">",
"      - Adherence to host cells and ECM proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H490215\">",
"      - Utilization of host proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14911866\">",
"      - Evasion of antibody-mediated killing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14911873\">",
"      - Evasion of complement-mediated killing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913313\">",
"      Host response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H490044\">",
"      - Cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543913321\">",
"      LATE DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913329\">",
"      Bacterial adaptations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543913337\">",
"      Host response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H490085\">",
"      - Antibody response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543913345\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=related_link\">",
"      Prevention of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26553="Prehospital pediatrics and emergency medical services (EMS)";
var content_f25_59_26553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prehospital pediatrics and emergency medical services (EMS)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Paul E Sirbaugh, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Garth Meckler, MD, MSHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Richard D Zane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26553/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/59/26553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/59/26553/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/59/26553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of emergency medical services, or EMS, encompasses many areas of emergency care, including the evaluation, management, and transport of patients from the scene of an injury or illness to their arrival at an emergency care facility (the out-of-hospital or prehospital care), as well as the management within the emergency department.",
"   </p>",
"   <p>",
"    EMS systems date back to the 18",
"    <sup>",
"     th",
"    </sup>",
"    century when Napoleon&rsquo;s surgeon-in-chief, Barron Larrey decreased mortality by transporting wounded soldiers rapidly to field hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, the EMS system formally began in 1966 with passage of the National Highway Traffic Safety Act that focused on the emergency care of trauma victims from motor vehicle crashes and tied federal funding for highway construction to development of state EMS systems.",
"   </p>",
"   <p>",
"    Recognizing that children have unique anatomic, physiologic, developmental and medical needs, the federal government passed legislation in 1984 that allocated funds for the purpose of improving the system for providing EMS for children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/2\">",
"     2",
"    </a>",
"    ], creating the Emergency Medical Services for Children Program (EMSC,",
"    <a class=\"external\" href=\"file://mchb.hrsa.gov/programs/emergencymedical/\">",
"     file://mchb.hrsa.gov/programs/emergencymedical/",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. EMSC is a collaborative program between Health Resources and Services Administration (HRSA), the Maternal and Child Health Bureau and the National Highway Traffic Safety Administration and provides funding to all 50 states and United States territories [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, all states have EMS legislation, providing the basis for statewide systems. However, state agencies and local jurisdictions (eg, municipalities or counties) have established local regulations regarding the extent of services that can be provided by prehospital personnel and the procedures that they may perform on children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EMS system, prehospital personnel and their capabilities, proper preparation and equipment for prehospital care of children, and advantages and disadvantages of different modes of transport will be reviewed here. The general approach to providing online medical direction and pediatric prehospital care considerations, including management, field triage, and transport decisions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=see_link\">",
"     \"Pediatric considerations in prehospital care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of United States pediatric emergency medical services (EMS) use has been described in a nationally representative sample taken from a database of almost 111 million pediatric emergency department (ED) visits [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/6\">",
"     6",
"    </a>",
"    ]. Children under the age of 19 account for approximately 27 percent of US emergency department visits, and 13 percent of all EMS transports. While only 7 percent of children treated in emergency departments arrive by ambulance, they are more likely than those who arrive by other means (eg, private vehicle) to require immediate care, treatment for trauma or poisoning, and admission to the hospital ward or intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-white race, urban environment, and lack of insurance are associated with EMS transport in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to children arriving to the emergency department by other means, those arriving by EMS are predominantly infants or adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Infants require transport most often for acute illness, ingestions, and seizures, whereas adolescents are most often transported in association with trauma (including motor vehicle crashes, suicide attempts, and assault) and alcohol and drug intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prehospital pediatric resuscitation is rare, and most often occurs in children younger than four years of age. Thus, it is important that EMS systems provide appropriately sized equipment and personnel properly trained in management of pediatric emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. However, the infrequency of prehospital pediatric resuscitation makes maintenance of skills challenging. As an example, of 1377 pediatric EMS transports in a Canadian system, only 2.4 percent involved life-threatening problems and very few transports involved bag-mask ventilation (0.3 percent), endotracheal intubation (0.1 percent), or administration of intravenous medications (1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF THE LAYPERSON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prehospital care of an injured or ill child is initiated by those who are present at the time of injury or acute illness, the \"bystanders.\" They are the ones who access the EMS system and begin life-saving interventions, including cardiopulmonary resuscitation (CPR) until EMS arrival.",
"   </p>",
"   <p>",
"    With involvement of the layperson, the crucial time between a life-threatening illness or injury and institution of emergency medical management can be reduced. Specific examples of the important role of bystanders include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple studies have demonstrated the importance of bystander involvement in witnessed cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/14-19\">",
"       14-19",
"      </a>",
"      ]. In fact, with the introduction of automated external defibrillators (AEDs), the role of the layperson has expanded beyond CPR into the management of ventricular fibrillation.",
"     </li>",
"     <li>",
"      Bystander intervention has been effective for removing a foreign body from the airway. In a study that compared bystander intervention with EMS intervention for the management of 103 children (aged 0 to 15 years) with foreign bodies in the airway, the airways were cleared before EMS arrival in 85 percent of the children, either by a bystander (47 percent) or the child (38 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/20\">",
"       20",
"      </a>",
"      ]. These findings support the AAP recommendation that new parents and other laypersons who care for children (eg, teachers, day care providers) be trained in CPR [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE EMS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common method of requesting EMS transport in the United States and Canada is via the 911 system. As a general rule, access to 911 is provided to the consumer through the local telephone service and routed to public safety answering points (PSAPs). The city or local community contracts with an EMS service to provide medical response and transport to 911 callers. However, 911 is not a universal emergency telephone number in other countries. As an example, 112 is the common emergency medical call number for European Union countries while 000 is used in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most emergency medical systems employ some version of enhanced 911, which provides the name, address, and phone number of the individual whose phone is used to place the emergency call. When cellular telephones are used to place 911 calls, the address and phone number that are provided to the PSAP point the dispatcher to the cellular telephone company, not to the caller. This problem is being addressed through the use of satellites that can pinpoint the exact location of the cellular telephone caller.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of EMS systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of EMS systems exist, and each has its own advantages and disadvantages. The three most common types are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      City or county",
"     </li>",
"     <li>",
"      Private",
"     </li>",
"     <li>",
"      Volunteer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     City/county (regional)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     city/county",
"    </span>",
"    type of EMS system is operated by the city, county, or regional government and usually is integrated into the fire department. Most commonly, the fire chief has significant control of the EMS division (which may be shared with the EMS medical director). Regional systems often are funded by the local municipality, providing at least a theoretical guarantee of service to the taxpayer. Higher than average salaries and benefits often result in the retention of experienced personnel. In addition, most police and fire departments are administrated through a municipal or county system, which allows for an integrated dispatch system that can be used by police, fire, and EMS. Such an integrated system can help coordinate the effort during an emergency. The disadvantages of the regional system include potential budgetary concerns and delays because of governmental bureaucracy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Private",
"    </span>",
"    &nbsp;&mdash;&nbsp;Private ambulance companies operate in urban, suburban, and rural communities. In some cities or counties, private companies provide 911 access, and in others, they have partnership agreements with the city or county EMS systems. As an example, the city may provide 911 service to the community, whereas the private ambulance company performs all interfacility transports. A private company seldom operates 911 access if a city or county EMS system is already in existence. Cooperation among private companies is rare, and competition may be present. Salaries usually are based upon hourly wages, and job turnover is a frequent problem. Although the emergency medical technicians (EMTs) practice under the medical director's license, most patient care is predetermined by protocols, rather than by direct contact with a physician. Although this is also true for some",
"    <span class=\"nowrap\">",
"     city/county",
"    </span>",
"    EMS systems, it is more common among the privately run systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Volunteer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rural communities, 911 access often is contracted to volunteers. Because many volunteer prehospital providers have a personal interest in EMS, their level of training usually is equal to or greater than that of the EMTs in municipal and private systems. However, their experience and training may be limited unless they have opportunities to gain experience at second jobs or via larger EMS systems in neighboring communities. In volunteer systems, particularly in rural areas, the distance between hospitals may be great, transportation times prolonged, and the scope of practice necessarily broad. Medical direction often is limited, and protocols commonly are employed to assist the EMT with patient care. Problems may arise as a result of budgetary constraints because funding typically is limited in rural communities.",
"   </p>",
"   <p>",
"    The Office of Rural Health Policy, a division of HRSA, provides a number of resources for rural communities in recognition of their unique EMS needs and challenges (",
"    <a class=\"external\" href=\"file://www.hrsa.gov/ruralhealth\">",
"     file://www.hrsa.gov/ruralhealth",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pediatric healthcare providers can play an important role in the development, implementation, and supervision of emergency medical services for children in rural communities as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide education about pediatric issues from prevention to rehabilitation,",
"     </li>",
"     <li>",
"      Assist with protocol writing, hospital care, and pediatric data accumulation and interpretation.",
"     </li>",
"     <li>",
"      Assure appropriate pediatric resuscitation equipment is available in physician offices, transport vehicles, and receiving facilities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39047?source=see_link\">",
"       \"Preparing an office practice for pediatric emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Help prehospital providers maintain their skills with pediatric emergencies by providing continuing medical education and pediatric office rotations.",
"     </li>",
"     <li>",
"      Serve as advocates for community and state legislation to support the goals of EMSC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10749933\">",
"    <span class=\"h3\">",
"     International EMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization regards EMS systems as an integral part of any functional health care system. However, less than half of the world&rsquo;s countries have a formal EMS system in place [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/25\">",
"     25",
"    </a>",
"    ]. If EMS exists in many poorer countries, these systems typically focus on trauma care. Implementation of an integrated trauma system has been shown to decrease mortality 15 to 20 percent in high-income western nations, and prehospital trauma life support programs in low and middle-income countries improve survival rates by decreasing out-of-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the developed world, despite national differences in organization and funding of comprehensive EMS systems, two main models for the delivery of pre-hospital care have emerged with distinct characteristics. The Anglo-American model (typified by the US and British EMS systems, but also used by South Africa and Canada) centers around the philosophy of rapid transport to definitive care. There is limited emphasis on interventions pre-hospital. Systems developed around the Anglo-American model are frequently associated with public safety (eg, fire departments), and care is provided by EMTs with medical oversight. In general, countries with this strategy have a well-developed specialty of emergency medicine and patients are transported directly to emergency departments for further stabilization and definitive care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, the Franco-German model of EMS (used by countries including France, Germany, Greece, Austria, the Nordic Countries, and Malta) focuses on scene-based stabilization and treatment. Rather than the notion of bringing the patient to the hospital, this model essentially brings the hospital to the patient. In order to accomplish this, physicians are key members of the EMS team and have the authority to provide advanced care and determine disposition in the field. These systems are usually associated with the larger health system rather than public safety. After field treatment, patients may remain at home or if further hospital care (inpatient) is needed, be transported directly to hospital wards rather than emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An emerging model of EMS care being explored in the United Kingdom is that of the Emergency Care Practitioner (ECP) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/33\">",
"     33",
"    </a>",
"    ]. According to the National Health Service, an ECP is an allied health professional with special training who functions with significant autonomy and is capable of providing pre-hospital emergency care as well as community-based primary care. This model of EMS delivery is currently under consideration in other countries, including Australia and New Zealand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365214\">",
"    <span class=\"h1\">",
"     DISPATCH PERSONNEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dispatch operations vary widely depending upon the EMS system and the city, county, or state in which it operates. For the purpose of this discussion, central dispatch, one of the most common methods of dispatch, will be used as the prototype.",
"   </p>",
"   <p>",
"    It is the responsibility of the EMS system (eg,",
"    <span class=\"nowrap\">",
"     city/county,",
"    </span>",
"    private, or volunteer) to assign personnel to central dispatch. As a general rule, all 911 calls go through central dispatch, where select personnel forward calls to the appropriate location based upon the caller's request. As an example, when a 911 call is received, the individual who receives it determines if the call is for fire, police, or EMS. If the call is for EMS, it is forwarded to trained personnel who will gather the necessary information from the caller and dispatch personnel to the scene",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    offer advice to the caller.",
"   </p>",
"   <p>",
"    Most dispatch systems use some form of computer-aided protocols, which are updated on a continuous basis. Each question on the protocol must be answered before the next question appears on the computer monitor. When a caller requests an ambulance, for example, they may be asked \"Is the victim breathing?\" The caller must respond before the dispatcher can move to the next step in the protocol. The protocol questions proceed through the airway, breathing, and circulation guidelines of BLS. From the information that is obtained, the dispatcher determines the type of unit (ALS or BLS, see below) to be dispatched and what advice should be given to the caller. For critical cases, the dispatcher may remain on the line until EMS personnel arrive on scene.",
"   </p>",
"   <p>",
"    First responders are frequently dispatched to the scene, regardless of the level of emergency. If the injury or illness appears life-threatening, additional advanced trained personnel are dispatched, and the first responder remains at the scene to assist with the rescue. Once the EMS personnel arrive at the scene, radio or cell phone contact with the base station usually is attempted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365267\">",
"    <span class=\"h2\">",
"     Base station personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The base station typically is staffed with EMS providers who have advanced training and experience. They help the field personnel with decision-making and provide additional medical direction. Medical direction is provided by base station personnel in a variety of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Off-line medical direction refers to protocols that have been created by physicians and EMS providers for use by the field personnel, in the absence of active physician direction. Many pediatric prehospital protocols exist but may vary from region to region. In the United States, national model pediatric prehospital protocols have been developed [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/34\">",
"       34",
"      </a>",
"      ]. However, adoption is voluntary and has not occurred in many jurisdictions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=see_link&amp;anchor=H7779305#H7779305\">",
"       \"Pediatric considerations in prehospital care\", section on 'Offline medical control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On-line medical direction implies immediate medical assistance with each call. An example of on-line medical control would be a base station, located in a Level 1 trauma center, which is answered by nurses or physicians 24 hours per day, seven days per week. In one retrospective review, online medical direction improved the appropriateness of vascular access and cardiac monitoring in children with respiratory illness [",
"      <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=see_link&amp;anchor=H7779219#H7779219\">",
"       \"Pediatric considerations in prehospital care\", section on 'Online medical control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A combination of off-line and on-line medical direction is most common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365274\">",
"    <span class=\"h2\">",
"     Supervisors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the size and type of the EMS system, there are usually well trained individuals designated to provide supervision, education, and quality assurance. These individuals usually are paramedics who have years of field experience and have furthered their education in patient care. The EMS system is extremely dependent upon these individuals, and the quality of care provided to the community often is a reflection of their direction and level of expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365281\">",
"    <span class=\"h2\">",
"     EMS direction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each state designates an EMS director whose office is responsible for credentialing the state's EMS systems and personnel. In addition, individual EMS systems are directed medically by a local physician who oversees the practice of his or her EMS personnel. The EMS personnel operate under the medical license of the medical director, whose directive can either limit or expand their scope of practice. The credentials and experience of the medical director depend on the availability of resources. A large urban EMS system may have an affiliation with a local academic institution that is willing to provide financial or personnel assistance. In fact, several systems have both an adult and a pediatric medical director, in sharp contrast to many rural communities that may have to share the resources of one medical director.",
"   </p>",
"   <p>",
"    The Accreditation Council for Graduate Medical Education (ACGME) has recognized EMS as a medical subspecialty and has developed requirements and core content for programs seeking accreditation through the American Board of Emergency Medicine (ABEM) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TRANSPORT PERSONNEL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some countries, such as France, Germany, and Italy, prehospital advanced life support is provided by or under the direct supervision of a physician [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/36\">",
"     36",
"    </a>",
"    ]. In the United States, physicians may rarely accompany paramedics during prehospital care, primarily in a supervisory, training, or observational role. However, most prehospital care is provided by providers who are not physicians.",
"   </p>",
"   <p>",
"    In the United States, the curriculum and methods of education, testing, certification, and scope of practice of emergency medical personnel historically have varied dramatically from one community to the next because accreditation, certification, and licensure have been the responsibility of individual states. In an attempt to standardize training and scope of practice, the National Highway and Traffic Safety Administration (NHTSA) convened a workshop in 1990 that produced a \"National EMS Education and Practice Blueprint\" recommending four levels of emergency medical technicians (EMTs):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First responder",
"     </li>",
"     <li>",
"      EMT-Basic (EMT-B)",
"     </li>",
"     <li>",
"      EMT-Intermediate (EMT-I)",
"     </li>",
"     <li>",
"      EMT-Paramedic (EMT-P)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The document addressed the education, training, and policies for each category of EMT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/37\">",
"     37",
"    </a>",
"    ]. Funding for the development of a national EMS curriculum, including didactic education, skills laboratory, clinical education, field internship, continuing education, and recertification, was provided by the United States Department of Transportation (DOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/38\">",
"     38",
"    </a>",
"    ]. The curricula for the various providers were completed between 1994 and 1999, and most states require that they be used in the training of EMS personnel. Recommended minimum training requirements of the various personnel include: approximately 40 hours for first responder, 110 hours for EMT-B, 800 to 100 hours for EMT-I, and 1000 to 1200 hours for EMT-P.",
"   </p>",
"   <p>",
"    More recently, NHTSA and HRSA convened a multidisciplinary task force to develop a comprehensive national system to maximize efficiency, consistency and quality of instruction, and student competence consisting of five components [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       EMS Core Content",
"      </strong>",
"      &ndash; A comprehensive list of the domains of knowledge and skills necessary to provide out-of-hospital emergency medical care; defines the universe of EMS knowledge and skills.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       EMS Scope of Practice Model",
"      </strong>",
"      &ndash; A delineation of provider practice and licensing levels designed to guide state legislation, clarify EMS roles for the community, and promote standardization and reciprocity among states. The new scope of practice model would replace the current designation of providers with four new levels of provider:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Emergency Medical Responder (EMR)",
"     </li>",
"     <li>",
"      Emergency Medical Technician (EMT)",
"     </li>",
"     <li>",
"      Advanced Emergency Medical Technician (AEMT)",
"     </li>",
"     <li>",
"      Paramedic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       EMS Education Standards",
"      </strong>",
"      &ndash; prescriptive new national standard curriculum with a set of minimum competencies, clinical behaviors, and judgments that must be met for each level of training as defined by the scope of practice model (",
"      <a class=\"external\" href=\"file://www.ems.gov/pdf/811077a.pdf\">",
"       www.ems.gov/pdf/811077a.pdf",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       EMS Education Program Accreditation",
"      </strong>",
"      &ndash; A proposal to develop and implement a national educational program accreditation process to verify educational quality and enhance consistency of pre-hospital education.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       EMS Certification",
"      </strong>",
"      &ndash; A proposal for a universal standardized examination process for each level of provider, contingent on graduation from a nationally accredited training program.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Implementation of the EMS Education Agenda has not yet been achieved, and national accreditation and certification standards have yet to be developed. Currently, most (but not all) states utilize the current national standard curricula and many require EMTs to pass the National Registry of Emergency Medical Technicians (NREMT) certification exam. Continuing education requirements for recertification also vary widely from state-to-state.",
"   </p>",
"   <p>",
"    Of note, most systems require that their EMT-P personnel have at least 10 percent of their training in pediatrics. Some systems rely on the Pediatric Advanced Life Support course (PALS) for their pediatric education, whereas others create their own educational experience in pediatrics. Instead of PALS, some systems use The Pediatric Education for Prehospital Professionals (PEPP) course for pediatric education. PEPP is a two-day program available to both the basic and advanced prehospital provider (",
"    <a class=\"external\" href=\"file://www.peppsite.com/\">",
"     www.peppsite.com/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Scope of practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scope of practice for first responders, emergency medical technician-Basic, emergency medical technician-Intermediate, and emergency medical technician-paramedic are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef78718 \" href=\"UTD.htm?25/19/25915\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83593 \" href=\"UTD.htm?41/35/42556\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     First responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first responder, by definition, is the first EMS provider to arrive on the scene. His or her presence in an EMS system, however, often depends on the resources of the community. In the new United States EMS scope of practice model, first responders will be replaced with the designation Emergency Medical Responder (EMR) although the practice model remains the same. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Education'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of these providers is to initiate immediate basic lifesaving care to critical patients with minimal equipment while awaiting further EMS response (",
"    <a class=\"graphic graphic_table graphicRef83593 \" href=\"UTD.htm?41/35/42556\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. These providers often are firefighters on ladder and pumper trucks or police, who arrive at the scene early and begin the initial management. Most cities have more firefighters than EMS providers and fewer fires than medical emergencies. As a result, EMS systems have started to capitalize on the availability of fire personnel and have begun to introduce them to patient care. In one prospective, multi-center study of adults with out-of-hospital cardiac arrest, the use of first-responders shortened the time to definitive intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/40\">",
"     40",
"    </a>",
"    ]. Such studies have not been performed in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     EMT-Basic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMT-B also is referred to as Basic or basic life support (BLS). EMT-Bs will be replaced with the designation Emergency Medical Technician (EMT) in the new United States scope of practice model. They provide basic emergency medical care and transportation and perform interventions with basic equipment. The scope of practice of EMT-Bs is broader than first responders (",
"    <a class=\"graphic graphic_table graphicRef83593 \" href=\"UTD.htm?41/35/42556\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. However, EMT-Bs are",
"    <strong>",
"     not",
"    </strong>",
"    trained in endotracheal tube or intravenous (IV) placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EMT-Bs are the major labor force of the EMS system. They provide transport for patients with most minor illnesses and injuries and, depending on the community, may be responsible for the transport of Level 1 (moderate to severe) trauma patients. EMT-Bs can transport Level 1 trauma patients if the scene is close to a Level 1 trauma center. In such circumstances, the patient's airway and spine are stabilized at the scene and he or she is transported to the nearest trauma center without delay; major management is deferred until arrival at the hospital. This type of transport is known as \"load and go.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     EMT-Intermediate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scope of practice for the EMT-I is similar to that of the EMT-P (",
"    <a class=\"graphic graphic_table graphicRef83593 \" href=\"UTD.htm?41/35/42556\">",
"     table 2",
"    </a>",
"    ). Although the United States National Standardized Curriculum recommends four levels of training, the EMT-Intermediate (EMT-I) has been less widely accepted than has the EMT-Basic or paramedic. Many states and local governments have difficulty placing EMT-I in the larger scheme of prehospital care. States often permit them to certify as EMT-I, only to have local governments limit their scope of practice to that of the EMT-B because the local government recognizes only the EMT-B and the paramedic.",
"   </p>",
"   <p>",
"    The designation of Advanced Emergency Medical Technician (AEMT) will replace EMT-I in the new Scope of Practice Model. AEMTs will provide basic and limited advanced emergency care and transport. Skills include suctioning of the intubated patient, physical assessment, and a number of procedures, such as placement of intravenous or intraosseous access, and administration of fluids and a limited number of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     EMT-Paramedic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMT-Paramedic (EMT-P) also is referred to as EMT-Advanced (EMT-A) and advanced life support (ALS). The scope of practice of the paramedic includes that of the EMT-B, as well as airway management, intravenous and intraosseous access, cardiac life support, administration of system specific and approved medications, advanced triage, and advanced newborn resuscitation (",
"    <a class=\"graphic graphic_table graphicRef78718 \" href=\"UTD.htm?25/19/25915\">",
"     table 1",
"    </a>",
"    ). The new Scope of Practice Model does not significantly change the skills required of paramedics in the current system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREPARATION AND EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation is essential to assuring fast and appropriate patient care during an emergency. Response and transport personnel always should be ready for a pediatric emergency. The response and transport personnel who are dispatched should rehearse mock scenarios and prepare their equipment en route to the scene. Proper equipment and thoughtful preparation increase the likelihood of a good outcome.",
"   </p>",
"   <p>",
"    In addition to the standard equipment and supplies determined by governmental agencies (eg, those needed for safe extrication of patients), there are guidelines for pediatric equipment and supplies for both basic and advanced life support ambulances (",
"    <a class=\"graphic graphic_table graphicRef82004 \" href=\"UTD.htm?36/57/37788\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59854 \" href=\"UTD.htm?35/2/35884\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The Broselow&reg; pediatric emergency measuring tape (Armstrong Medical Industries, Lincolnshire, IL), or a similar resource, should be available on every vehicle. The measuring tape provides a rapid estimate of a child's weight from the recumbent length and correlates the child's size with appropriate sizes of emergency equipment and doses for emergency medications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     AIR VERSUS GROUND TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to transport a child by air or ground depends upon the condition of the child, the severity of the emergency condition, the type and location of the emergency facility, local resources, safety, the pediatric medical skill set of the potential providers, and weather conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. As a general rule, ground transport is more readily available if an emergency facility is within 20 to 30 minutes of the scene, and air transport is better if there is rough terrain or a long distance between the scene and the emergency facility. Sometimes a combination of air and ground transport is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ground transportation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulances used for ground transportation are categorized according to their equipment and staffing as BLS vehicles or ALS vehicles. BLS vehicles should carry (at minimum) the equipment identified by the American College of Surgeons as essential (",
"    <a class=\"graphic graphic_table graphicRef82004 \" href=\"UTD.htm?36/57/37788\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. The staffing varies, but BLS units usually have at least two persons trained to the level of EMT-B. ALS vehicles should have at least one paramedic on board. In addition to meeting the standards for BLS vehicles, ALS vehicles should have intubation and vascular access equipment, a portable battery operated monitor-defibrillator, and a variety of medications (",
"    <a class=\"graphic graphic_table graphicRef59854 \" href=\"UTD.htm?35/2/35884\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ALS response is required if the child has a life-threatening problem, alteration of consciousness, or respiratory distress, or potentially requires airway management or vascular access. A BLS response may be more appropriate and expeditious for limb-threatening problems and those requiring first-aid, immobilization, oxygen administration, and immediate transport (eg, \"load and go\"). All other problems may receive a less acute mode of transport [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Air transportation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air transportation, which requires specialized equipment and staffing, can occur via helicopter or fixed-wing planes. Helicopters are used more often in densely populated areas; they have the advantage of rapid, direct access to the scene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, helicopters can provide ALS services to large, rural areas that are unable to sustain independent ALS units. Helicopter response teams usually are reserved for short-range transports and those instances in which ground transport would result in unacceptable delays. The teams that operate helicopter transports often are comprised of paramedics, nurses, and occasionally, physicians who are trained and experienced in the delivery of advanced cardiac life support.",
"   </p>",
"   <p>",
"    Fixed-wing vehicles provide smoother, quieter, faster, and more spacious transportation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/5\">",
"     5",
"    </a>",
"    ]. However, because they require a runway for take-off and landing, they are not capable of providing direct scene access. If distances between referral hospitals are greater than 150 miles, the patient probably should be transported by fixed-wing aircraft. Most tertiary pediatric care facilities offer fixed-wing transports through leasing agreements with local airports or airline companies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Special considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;During air transportation of sick neonates and children the effects of hypoxemia, gravitational forces, expansion of trapped gases, and decreased temperature and humidity must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate oxygenation is best assessed with continuous pulse oximetry and adjustment of fractional inspired oxygenation concentration.",
"     </li>",
"     <li>",
"      The expansion of gases trapped in body cavities may have adverse consequences (eg, pneumothorax) if this effect of altitude is not anticipated and managed (eg, by air venting or use of pressurized cabins).",
"     </li>",
"     <li>",
"      Temperature regulation should be maintained since hypothermia and shivering increase oxygen consumption and may aggravate metabolic derangements (eg, acidosis, hypoglycemia).",
"     </li>",
"     <li>",
"      Maintenance of humidity can facilitate temperature control and fluid balance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     QUALITY IMPROVEMENT AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giving attention to quality improvement (QI) programs and safety is essential to providing good patient care. Most EMS systems have some form of QI built into their program. Quality improvement programs are particularly important when instituting new or controversial procedures (eg, endotracheal intubation) into the paramedic's scope of practice. As an example, one controlled clinical trial indicated that the addition of endotracheal intubation to a paramedic scope of practice that already included bag mask ventilation did not alter survival or neurologic outcomes of children undergoing short transport times to definitive care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/3\">",
"     3",
"    </a>",
"    ]. The study also demonstrated that mortal complications of intubation (eg, esophageal intubation, unrecognized dislodgement of the endotracheal tube) occurred in 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the risks of endotracheal intubation in some EMS systems may outweigh the benefits of intubation that have been identified in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring outcomes when procedures or policies are changed is necessary to determine whether such procedures or policies are successful and is essential to providing optimal patient care and safety. A key aspect of monitoring is detailed assessment of adverse events and near-misses to determine root causes and effective strategies for prevention. As an example, a small observational study of adverse events and near-misses in pediatric prehospital care identified the following key issues [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress and anxiety caused by decreased experience with pediatric patients",
"     </li>",
"     <li>",
"      Inadequate training and experience in managing children in the prehospital environment",
"     </li>",
"     <li>",
"      Concern about causing pain or harm",
"     </li>",
"     <li>",
"      Predominance of errors of omission (failure to act when it is indicated) over errors of commission (performing the procedure incorrectly or doing the wrong intervention)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delineation of the epidemiology of errors and near misses related to the prehospital care of children remains an area of emerging interest and few data exist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. An excellent guide to quality improvement for emergency medical service systems is available through NHTSA (",
"    <a class=\"external\" href=\"file://www.nhtsa.gov/people/injury/ems/leaderguide\">",
"     file://www.nhtsa.gov/people/injury/ems/leaderguide",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TRANSPORT REFUSAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refusal of transport by a legal guardian or a prehospital provider is an important occurrence that should be addressed with standard policies and procedures and according to the laws of the jurisdiction. Transport refusal is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=see_link&amp;anchor=H1565379#H1565379\">",
"     \"Pediatric considerations in prehospital care\", section on 'Transport refusal by legal guardian'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=see_link&amp;anchor=H2111936#H2111936\">",
"     \"Pediatric considerations in prehospital care\", section on 'Decision not to transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10751377\">",
"    <span class=\"h1\">",
"     INTER-FACILITY TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, preparation is essential to good patient care. Although most hospitals are not expected to provide tertiary pediatric care, they should be prepared to stabilize infants and children who present for care. That preparation includes having a prearranged transfer agreement that identifies the preferred tertiary pediatric care facility, mode of transport, and method of contact and a similar agreement with an EMS provider. In some situations the transport service is provided through the municipal EMS service; more commonly, the contract is assigned to a private company or hospital transport service. Large tertiary care facilities may operate their own ambulance service, including air transport, or contract the service with a private EMS company. A guide for interfacility patient transfer has been published by NHTSA and is available through their website (",
"    <a class=\"external\" href=\"file://www.nhtsa.gov/people/injury/ems/interfacility/index.htm\">",
"     file://www.nhtsa.gov/people/injury/ems/interfacility/index.htm",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Use of a pediatric specialized team is associated with improved survival and fewer adverse events during transport [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The use of pediatric specialized teams is recommended whenever it is available. For example, an observational study of adverse events and mortality occurring during interfacility transports, involving 1085 infants and children (1021 transported by a pediatric team and 64 transported by a nonspecialized team), reported an overall frequency of 64 unplanned adverse events (UAE) experienced by 55 children (5 percent of all patients) and 117 deaths (10 percent of all patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/53,55\">",
"     53,55",
"    </a>",
"    ]. Medical control was provided by the same group of pediatric critical care specialists for all transports. The risk of UAE was much higher for children transported by a nonspecialized team versus a pediatric team (20 percent versus 0.5 percent; adjusted RR 246, 95 % CI: 76-796). In addition, mortality was greater among children transported by a nonspecialized team than by a pediatric team (23 percent (15 patients) versus 9 percent (92 patients); adjusted RR 2.5, 95% CI: 1.1-5.3). In this study, for every seven transports by a nonspecialized team, approximately one unexpected death occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?25/59/26553/abstract/55\">",
"     55",
"    </a>",
"    ]. These differences in unexpected outcomes during transport occurred despite a significantly longer transport time for the pediatric team versus the nonspecialized team (mean time 113 minutes versus 81 minutes, p&lt;0.001).",
"   </p>",
"   <p>",
"    The most common scenario that leads to an inter-facility transport involves the critically ill neonate, infant, or child who requires services not available at the transferring facility. Depending upon the severity of the child's illness or injury, the receiving hospital may choose to send a critical care transport team to pick up the child. In such a situation, the receiving hospital usually provides advice to the referring hospital awaiting the transport team's arrival.",
"   </p>",
"   <p>",
"    Stabilizing the critically ill or injured patient before transfer is necessary to assure a good patient outcome. Crucial stabilization and management interventions should not wait for arrival of a pediatric transport team but should be identified and performed with assistance and off site direction from a pediatric transport medical command physician.",
"   </p>",
"   <p>",
"    Most tertiary pediatric care facilities send a critical care transport team to the referring facility and attempt to stabilize the patient at the referring facility before performing the transport. Tertiary pediatric care facilities often have a critical care response team(s) available. These are often limited resources, however, and may not always be immediately available. The personnel that comprise the hospital transport team usually include a combination of two or more of the following transport trained providers (physician, nurse or paramedic, respiratory therapist). Most personnel are certified in pediatric advanced life support and often are staff members of the emergency department, pediatric intensive care unit, or neonatal intensive care unit.",
"   </p>",
"   <p>",
"    Other circumstances that may result in an inter-facility transport include those initiated at the family's request or in accordance with insurance contract requirements. In these cases, involving the critical care transport team may not be necessary, and an EMS service with properly trained personnel can often fulfill the need.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365041\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency medical services (EMS) system encompasses all medical care delivered prior to hospital arrival from bystander notification and first aid to advanced therapies provided by a licensed paramedic or, in some countries, a physician. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'The EMS system'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Key components of the system include a universal telephone number to request EMS assistance (eg, 911 in the United States or Canada, 112 in European Union countries), dispatch personnel to answer emergency calls and to send EMS personnel, and dedicated and licensed EMS personnel with a pre-defined scope of practice and standardized training or, in some countries, physicians who provide prehospital care and rapid hospital transport. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The EMS system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H365214\">",
"       'Dispatch personnel'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Transport personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Globally, EMS systems are rudimentary in impoverished countries. In wealthier nations, variable organization and funding strategies primarily focus around one of two delivery strategies: &ldquo;scoop and run,&rdquo; as exemplified by the Anglo-American model; and &ldquo;stay and treat,&rdquo; typified by the Franco-German model. The former relies on care provided by providers who are not physicians with medical oversight while the latter provides on-site care by trained physicians. (See",
"      <a class=\"local\" href=\"#H10749933\">",
"       'International EMS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the US, the organization of EMS occurs at the local and state levels with federal support from multiple agencies that provide limited funding for each state system as well as research funds targeting EMS issues. Considerable variation in prehospital provider training, certification, licensure, and continuing education as well as scope of practice (",
"      <a class=\"graphic graphic_table graphicRef78718 \" href=\"UTD.htm?25/19/25915\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83593 \" href=\"UTD.htm?41/35/42556\">",
"       table 2",
"      </a>",
"      ) currently exists, though federal efforts are underway to establish national standards. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of EMS systems'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Transport personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant portion of prehospital emergency medical services transports involve children. Thus, it is essential that EMS systems provide equipment that is of the appropriate size to use in children of various ages and personnel properly trained in pediatric emergency care, particularly in management of the pediatric airway. In addition to the standard equipment and supplies determined by governmental agencies (eg, those needed for safe extrication of patients), there are guidelines for pediatric equipment and supplies for both basic and advanced life support ambulances (",
"      <a class=\"graphic graphic_table graphicRef82004 \" href=\"UTD.htm?36/57/37788\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef59854 \" href=\"UTD.htm?35/2/35884\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Preparation and equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to transport a child by air or ground depends upon the condition of the child, the severity of the emergency condition, the type and location of the emergency facility, the pediatric medical capability of the transporting personnel, local resources, safety, and weather conditions. Ground transport is more readily available if an emergency facility is within 20 to 30 minutes of the scene, and air transport is better if there is rough terrain or a long distance between the scene or transferring facility and the receiving facility. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Air versus ground transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During inter-facility transport, use of a pediatric specialized team is associated with significantly improved survival and fewer adverse events. Thus, whenever possible, a pediatric transport team should be used for interfacility transportation of critically ill or injured children. (See",
"      <a class=\"local\" href=\"#H10751377\">",
"       'Inter-facility transport'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/1\">",
"      Skandalakis PN, Lainas P, Zoras O, et al. \"To afford the wounded speedy assistance\": Dominique Jean Larrey and Napoleon. World J Surg 2006; 30:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/2\">",
"      Seidel JS. Emergency medical services and the pediatric patient: are the needs being met? II. Training and equipping emergency medical services providers for pediatric emergencies. Pediatrics 1986; 78:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/3\">",
"      Gausche M, Lewis RJ, Stratton SJ, et al. Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome: a controlled clinical trial. JAMA 2000; 283:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/4\">",
"      Ludwig S, Selbst S. A child-oriented emergency medical services system. Curr Probl Pediatr 1990; 20:109.",
"     </a>",
"    </li>",
"    <li>",
"     Woodward GA, King BR, Garrent AL, Baker MD. Prehospital care. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2006. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/6\">",
"      Shah MN, Cushman JT, Davis CO, et al. The epidemiology of emergency medical services use by children: an analysis of the National Hospital Ambulatory Medical Care Survey. Prehosp Emerg Care 2008; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/7\">",
"      Richard J, Osmond MH, Nesbitt L, Stiell IG. Management and outcomes of pediatric patients transported by emergency medical services in a Canadian prehospital system. CJEM 2006; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/8\">",
"      Tsai A, Kallsen G. Epidemiology of pediatric prehospital care. Ann Emerg Med 1987; 16:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/9\">",
"      Weiss SJ, Ernst AA, Phillips J, Hill B. Visits to home environments by emergency medical services: a statewide study. Prehosp Emerg Care 2001; 5:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/10\">",
"      Seidel JS, Henderson DP, Ward P, et al. Pediatric prehospital care in urban and rural areas. Pediatrics 1991; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/11\">",
"      Yamamoto LG, Wiebe RA, Maiava DM, Merry CJ. A one-year series of pediatric prehospital care: I. Ambulance runs; II. Prehospital communication; III. Interhospital transport services. Pediatr Emerg Care 1991; 7:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/12\">",
"      Sapien RE, Fullerton L, Olson LM, et al. Disturbing trends: the epidemiology of pediatric emergency medical services use. Acad Emerg Med 1999; 6:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/13\">",
"      Scribano PV, Baker MD, Holmes J, Shaw KN. Use of out-of-hospital interventions for the pediatric patient in an urban emergency medical services system. Acad Emerg Med 2000; 7:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/14\">",
"      Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from sudden cardiac arrest: the \"chain of survival\" concept. A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation 1991; 83:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/15\">",
"      Ritter G, Wolfe RA, Goldstein S, et al. The effect of bystander CPR on survival of out-of-hospital cardiac arrest victims. Am Heart J 1985; 110:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/16\">",
"      Cummins RO, Eisenberg MS. Prehospital cardiopulmonary resuscitation. Is it effective? JAMA 1985; 253:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/17\">",
"      Roth R, Stewart RD, Rogers K, Cannon GM. Out-of-hospital cardiac arrest: factors associated with survival. Ann Emerg Med 1984; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/18\">",
"      Cummins RO, Eisenberg MS, Hallstrom AP, Litwin PE. Survival of out-of-hospital cardiac arrest with early initiation of cardiopulmonary resuscitation. Am J Emerg Med 1985; 3:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/19\">",
"      Berg RA, Hilwig RW, Kern KB, Ewy GA. \"Bystander\" chest compressions and assisted ventilation independently improve outcome from piglet asphyxial pulseless \"cardiac arrest\". Circulation 2000; 101:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/20\">",
"      Andazola JJ, Sapien RE. The choking child: what happens before the ambulance arrives? Prehosp Emerg Care 1999; 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     The pediatrician's role in advocating life support courses for parents (RE9424). American Academy of Pediatrics. Committee on Pediatric Emergency Medicine. AAP News, 1994. (www.aap.org/policy/570.html).",
"    </li>",
"    <li>",
"     Single European emergency call number 112. file://ec.europa.eu/echo/civil_protection/civil/prote/112/112_en.htm (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     Triple zero (000). Australian Government. file://www.triplezero.gov.au (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/24\">",
"      Moore B, Sapien R, Committee on Pediatric Emergency Medicine. The role of the pediatrician in rural emergency medical services for children. Pediatrics 2012; 130:978.",
"     </a>",
"    </li>",
"    <li>",
"     Sasser S, Varghese M, Kellermann A, Lormand J. Prehospital trauma care systems. 2005. file://www.who.int/violence_injury_prevention/publications/services/39162_oms_new.pdf (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/26\">",
"      Husum H, Gilbert M, Wisborg T, et al. Rural prehospital trauma systems improve trauma outcome in low-income countries: a prospective study from North Iraq and Cambodia. J Trauma 2003; 54:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/27\">",
"      Al-Shaqsi S. Models of International Emergency Medical Service (EMS) Systems. Oman Med J 2010; 25:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/28\">",
"      MacFarlane C, van Loggerenberg C, Kloeck W. International EMS systems in South Africa--past, present, and future. Resuscitation 2005; 64:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/29\">",
"      Symons P, Shuster M. International EMS Systems: Canada. Resuscitation 2004; 63:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/30\">",
"      Black JJ, Davies GD. International EMS systems: United Kingdom. Resuscitation 2005; 64:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/31\">",
"      Adnet F, Lapostolle F. International EMS systems: France. Resuscitation 2004; 63:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/32\">",
"      Langhelle A, Lossius HM, Silfvast T, et al. International EMS Systems: the Nordic countries. Resuscitation 2004; 61:9.",
"     </a>",
"    </li>",
"    <li>",
"     NHS Modernisation Agency, Department of Health. The Emergency Care Practitioner Report: Right Skill, Right Time, Right Place.  Crown Copyright. COI Communications for the Department of Health 2004. file://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4093086 (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     Model pediatric protocols. EMSC partnership for children. National Association of EMS Physicians, 2003. file://www.kdheks.gov/cphp/download/cacs_template/ModelPediatricProtocols.pdf (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     Emergency Medical Services. Subspecialty Certification. American Board of Emergency Medicine file://www.abem.org/PUBLIC/portal/alias__rainbow/lang__en-US/tabID__4142/DesktopDefault.aspx (Accessed on May 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/36\">",
"      Fleischmann T, Fulde G. Emergency medicine in modern Europe. Emerg Med Australas 2007; 19:300.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Transportation, National Highway and Traffic Safety Administration, National EMS Education and Practice Blueprint.",
"    </li>",
"    <li>",
"     United States Department of Transportation, National Highway and Traffic Safety Administration, National Standard Curriculum.",
"    </li>",
"    <li>",
"     EMS Education Agenda for the Future: A Systems Approach www.nhtsa.gov/people/injury/ems/FinalEducationAgenda.pdf (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/40\">",
"      Hoekstra JW, Banks JR, Martin DR, et al. Effect of first-responder automated defibrillation on time to therapeutic interventions during out-of-hospital cardiac arrest. The Multicenter High Dose Epinephrine Study Group. Ann Emerg Med 1993; 22:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/41\">",
"      Guidelines for pediatric equipment and supplies for basic and advanced life support ambulances. Committee on Ambulance Equipment and Supplies, National Emergency Medical Services for Children Resource Alliance. Ann Emerg Med 1996; 28:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/42\">",
"      American College of Surgeons Committee on Trauma, American College of Emergency Physicians, National Association of EMS Physicians, et al. Policy statement--Equipment for ambulances. Pediatrics 2009; 124:e166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/43\">",
"      Argall JA, Wright N, Mackway-Jones K, Jackson R. A comparison of two commonly used methods of weight estimation. Arch Dis Child 2003; 88:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/44\">",
"      Black K, Barnett P, Wolfe R, Young S. Are methods used to estimate weight in children accurate? Emerg Med (Fremantle) 2002; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/45\">",
"      Hofer CK, Ganter M, Tucci M, et al. How reliable is length-based determination of body weight and tracheal tube size in the paediatric age group? The Broselow tape reconsidered. Br J Anaesth 2002; 88:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/46\">",
"      Gausche M, Seidel JS. Out-of-hospital care of pediatric patients. Pediatr Clin North Am 1999; 46:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/47\">",
"      Samuels MP. The effects of flight and altitude. Arch Dis Child 2004; 89:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/48\">",
"      Sirbaugh PE, Pepe PE, Shook JE, et al. A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest. Ann Emerg Med 1999; 33:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/49\">",
"      Cushman JT, Fairbanks RJ, O'Gara KG, et al. Ambulance personnel perceptions of near misses and adverse events in pediatric patients. Prehosp Emerg Care 2010; 14:477.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. To Err is Human: Building A Safer Health System. Washington, DC: Institution of Medicine of the National Academies, 1999.",
"    </li>",
"    <li>",
"     Institute of Medicine. Future of Emergency Care Series, Emergency Care for Children: Growing pains. Washington, DC: Institution of Medicine of the National Academies, 2006.",
"    </li>",
"    <li>",
"     Institute of Medicine. Future of Emergency Care Series, Emergency Medical Services at the Crossroads. Washington, DC: Institution of Medicine of the National Academies, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/53\">",
"      Orr RA, Felmet KA, Han Y, et al. Pediatric specialized transport teams are associated with improved outcomes. Pediatrics 2009; 124:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/54\">",
"      Edge WE, Kanter RK, Weigle CG, Walsh RF. Reduction of morbidity in interhospital transport by specialized pediatric staff. Crit Care Med 1994; 22:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/59/26553/abstract/55\">",
"      McPherson ML, Graf JM. Speed isn't everything in pediatric medical transport. Pediatrics 2009; 124:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5796 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.24-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26553=[""].join("\n");
var outline_f25_59_26553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365041\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF THE LAYPERSON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE EMS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of EMS systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - City/county (regional)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Private",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Volunteer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10749933\">",
"      - International EMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365214\">",
"      DISPATCH PERSONNEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365267\">",
"      Base station personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365274\">",
"      Supervisors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365281\">",
"      EMS direction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TRANSPORT PERSONNEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Scope of practice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - First responders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - EMT-Basic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - EMT-Intermediate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - EMT-Paramedic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREPARATION AND EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      AIR VERSUS GROUND TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ground transportation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Air transportation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Special considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      QUALITY IMPROVEMENT AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TRANSPORT REFUSAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10751377\">",
"      INTER-FACILITY TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365041\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/5796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/5796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/19/25915\" title=\"table 1\">",
"      EMT-P scope of practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/35/42556\" title=\"table 2\">",
"      US prehospital provider scope of practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/57/37788\" title=\"table 3\">",
"      Pediatric ambulance equipment for basic life support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/2/35884\" title=\"table 4\">",
"      Pediatric ambulance equipment for advanced life support",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/28/26057?source=related_link\">",
"      Pediatric considerations in prehospital care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39047?source=related_link\">",
"      Preparing an office practice for pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_59_26554="Healing by primary and secondary intention";
var content_f25_59_26554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Healing by primary and secondary intention",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McConnell TH. The Nature Of Disease: Pathology for the Health Professions, Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26554=[""].join("\n");
var outline_f25_59_26554=null;
var title_f25_59_26555="Risk factors for BOS";
var content_f25_59_26555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for bronchiolitis obliterans syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Probable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute rejection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphocytic bronchitis/bronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CMV pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Medication noncompliance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary graft dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Potential",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CMV infection (without pneumonitis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Organizing pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent infection other than CMV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Older donor age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prolonged allograft ischemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Donor antigen-specific reactivity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hypothetical",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Underlying cause of lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HLA-mismatching",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastroesophageal reflux with aspiration",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Estenne, M, Maurer, JR, Bohler,A, et al. Bronchiolitis obliterans syndrome 2001: An update of thediagnostic criteria. J Heart Lung Transplant 2002; 21:297.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26555=[""].join("\n");
var outline_f25_59_26555=null;
var title_f25_59_26556="HSV labor neonatal outcome";
var content_f25_59_26556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of women with genital HSV infection acquired near the time of labor and the associated neonatal outcome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient No.",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prenatal serologic status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serologic status during labor",
"       </td>",
"       <td class=\"subtitle1\">",
"        HSV type isolated during labor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms at seroconversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        HSV-1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        HSV-1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-1-positive",
"       </td>",
"       <td>",
"        HSV-2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table summarizes the characteristics of nine women who acquired genital HSV infection around the time of delivery, as determined&nbsp;by the isolation of HSV from a genital swab at&nbsp;labor in the setting of no antibodies or antibodies to a different HSV type detected at labor.",
"    <div class=\"footnotes\">",
"     HSV: herpes simplex virus; NA: not available.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Brown ZA, Selke S, Zeh J, et al. The Acquisition of Herpes Simplex Virus during Pregnancy. N Engl J Med 1997; 337:509.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26556=[""].join("\n");
var outline_f25_59_26556=null;
var title_f25_59_26557="IV vs PO calcitriol in ESRD";
var content_f25_59_26557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing effect of pulse intravenous versus oral calcitriol on parathyroid hormone and alkaline phosphatase in ESRD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulse intravenous calcitriol (IV CT) lowers the plasma levels of both parathyroid hormone (PTH, in pmol/L) and alkaline phosphatase (AP, in IU/L) in patients with end-stage renal disease. In comparison, daily oral calcitriol (PO CT) was essentially without benefit. The upper limit of normal was 9.5 pmol/L for PTH and 120 IU/L for alkaline phosphatase. There were no differences in the plasma concentrations of calcium, phosphate, or calcitriol with the two regimens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Oettinger CW, Oliver JC, Macon EJ, J Am Soc Nephrol 1992; 3:995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26557=[""].join("\n");
var outline_f25_59_26557=null;
var title_f25_59_26558="Contents: Lipid disorders";
var content_f25_59_26558=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lipid disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lipid disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31222\">",
"           Measurement of serum lipids and lipoproteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17015\">",
"           Effects of exercise on lipoproteins and hemostatic factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29546\">",
"           Lipid abnormalities after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10613\">",
"           ATP III guidelines for treatment of high blood cholesterol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2601\">",
"           Dietary fat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3002\">",
"           Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/63/10230\">",
"           Statins: Possible noncardiovascular benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/32/26122\">",
"           Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-82C9FAB42B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_59_26558=[""].join("\n");
var outline_f25_59_26558=null;
var title_f25_59_26559="Peritoneal endometriosis";
var content_f25_59_26559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peritoneal endometriosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peritoneum in this woman with endometriosis is studded with reddish, irregularly shaped implants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Copyright 1990 Syntex Laboratories, Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_59_26559=[""].join("\n");
var outline_f25_59_26559=null;
